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ABSTRACT 
 The short chain fatty acid (SCFA) butyrate, a main end product of microbial 
fermentation of dietary fibers in human intestine, plays an important role in the 
maintenance of intestinal homeostasis and overall health status. The effects exerted by 
butyrate are multiple and involve several distinct mechanisms of action including 
epigenetic modifications owing to its inhibitory effects on histone deacetylases, inhibition 
of NF-κB signaling, or direct agonism on the free fatty acid receptors.  
 At intestinal level, butyrate is the major energy source for colonocytes and acts 
regulating epithelial cell proliferation, defense barrier, visceral sensitivity and motility, 
preventing and inhibiting colonic carcinogenesis. Recent experimental evidence has 
suggested potential extra-intestinal therapeutic applications of butyrate, including the 
treatment of systemic diseases, among these not only metabolic and inflammatory 
disorders but also cystic fibrosis, urea cycle enzyme deficiency, X-linked 
adrenoleukodystrophy. 
 Data from literature and clinical evidence of several research groups show a wide 
spectrum of possibilities for potential therapeutic use of butyrate by oral administration 
without having serious adverse effects. Some butyrate-based products are marketed, but 
their spread is still very limited and greatly understaffed in view of the wide spectrum of 
possible indications, especially in chronic diseases, where it is possible to predict a lasting 
use of the compound. The main problem is the availability of butyrate formulations that 
could overcome the main limitations to the use of butyrate in the therapeutic field, namely 
its instability and poor palatability. In fact, the unpleasant taste and odour make oral 
administration of butyrate extremely difficult, especially in children.  
On the basis of its characteristics, butyrate can be considered a “postbiotic” being a non-
viable bacterial metabolic product obtained from probiotic microorganisms that have 
biologic activity in the host. The direct use of postbiotics, such as butyrate, may be 
potential alternatives to the use of live probiotic organisms or to dietary fiber intake as 
prebiotics exerting several and similar beneficial regulatory effects on host biological 
functions. Even if a growing number of studies has revealed new mechanisms and effects 
of butyrate with a wide range of potential clinical applications from the intestinal tract to 
peripheral tissues, more data are needed to elucidate the efficacy of butyrate in 
gastrointestinal and extra-intestinal diseases and new solutions for an easier administration. 
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To date, several studies have evaluated butyrate effectiveness in several animal models of 
colitis. In humans few studies have been performed probably due to low compliance for 
the oral route (for its rancid taste) or rectal enemas administration (for its cumbersome 
application to the patient and irritability due to acid property). 
Here, about its intestinal effects, we examined the efficacy of oral butyrate and its 
derivative N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA), as preventive or therapeutic 
treatment in a murine model of DSS-induced colitis. Both compounds are able to recover 
the imbalance between pro-inflammatory and anti-inflammatory mediators, altered in 
colitis and restore gut permeability, avoiding bacterial translocation and modulating 
immune cell recruitment. Butyrate anti-inflammatory effects are associated not only to the 
reduction in neutrophil infiltration and HDAC9 transcription in colonic mucosa, but also 
the restoration of PPAR-γ expression and inhibition of NF-kB activation, protecting 
colonocytes from inflammation. 
 Alterations in the microbiota have now been implicated in the pathogenesis of some 
diseases, including food allergy. Intestinal microbiota influences immune system network 
and impairs its regulatory functions. Allergic infants exhibit an accelerated evolution of 
microbiota more typical of the adult one with a significantly reduced abundance of 
butyrate-producing species, such as Lactobacillales and Bifidobacteriales, and increased 
abundance of Clostridiales. Animal models of food allergy have emerged as tool for 
identifying mechanisms involved in the development of sensitization to normally harmless 
food allergens, as well as delineating the critical immune components of the effect or phase 
of allergic reactions to food. One of the critical advantages of using mouse models to study 
food allergy is that allergic sensitization or tolerance can be induced to specific allergens 
under controlled environmental conditions within defined genetic backgrounds, which is 
not possible in human subjects. This aspect of mouse models allows extensive and precise 
investigations into the mechanisms involved in disease etiology and responsible for loss of 
tolerance in patients, identifying new targets and efficacious therapies. Increasing evidence 
from several mouse models indicates that alterations in regulatory T (Treg) cell function 
and environmental factors, such as microbiota, are likely important contributors to allergic 
sensitization and food allergy. Here, we used a model of cow's milk allergy (CMA) 
induced in mice. 
 In this experimental model of CMA the preventive and therapeutic effects of oral 
sodium butyrate administration were evaluated. Butyrate was able to suppress acute skin 
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response to the β-lactoglobulin (BLG) allergen, one of the most important cow’s milk 
proteins, and to reduce anaphylactic symptoms and immediate immune response. 
Furthermore, butyrate ability to improve gut permeability was also shown, reducing 
plasma levels of FITC-Dextran evaluated after oral administration. Butyrate reduced ear 
swelling, hypersensitivity symptoms and limited the decrease of body temperature after 
BLG challenge. Moreover, butyrate decreased the innate immune response, reducing IgE 
and IL-4 levels. 
 About butyrate extra-intestinal effect, our study was focused on osteoarthritis (OA), 
the most common form of arthritis worldwide, whose development is increased by aging, 
obesity and biomechanical injury. It is a cartilage degenerative disease where chondrocytes 
play a central role. In fact, in OA chondrocyte phenotype changes and apoptosis and 
extracellular matrix degradation occur. Using an in vitro model, we demonstrated the effect 
of sodium butyrate in reducing inflammatory mediators and pathways in chondrocytes 
activated by IL-1, and, more interestingly, we showed that its chemoattractant activity is 
mediated by GPR43. Butyrate, not only reduced pro-inflammatory cytokines and 
adipokines involved in OA, but also decreased the expression of several adhesion 
molecules, inhibiting inflammatory and anti-apoptotic pathways. We also show the 
butyrate capability to reduce MMPs production and the loss of collagen type 2, suggesting 
an improvement of cartilage disruption. Interestingly, butyrate anti-inflammatory effects 
were associated to its capability to stimulate neutrophil recruitment, increasing the 
expression of important chemokines (Ccl3 and Cx3cl1) and anti-inflammatory protein 
AnxA1, suggesting butyrate pro-resolving activity during inflammatory response. The 
novelty of our data is the involvement of GPR43 in the chemoattractant activity of butyrate 
in IL-1-stimulated chondrocytes. In fact, butyrate failed to induce the expression of Cx3cl1 
and AnxA1 in GPR43-silenced cells, missing its chemoattractant effect. 
The pro-resolving effect of butyrate was also analyzed in two models of wound 
healing induced by doxorubicin or mechanical damage. In tissue repair the immediate goal 
is to achieve tissue integrity, homeostasis and wound healing. Tissue injury causes the 
immediate onset of acute inflammation. The healing process involves three phases that 
overlap in time and space: inflammation, tissue formation, and tissue remodeling. 
Synthesis, remodeling, and deposition of structural extracellular matrix molecules and 
soluble mediators, are indispensable for initiating repair and progression into the healing 
state. In our study, we demonstrated that butyrate and FBA treatments accelerate and 
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promote wound resolution process. In our experimental models, we showed that butyrate 
and its derivative FBA reduced the repair time when used systemically (by oral 
administration) or topically (by intradermal injection). This protective effect appeared to be 
time- and concentration-dependent. 
 In summary, we have demonstrated the multiple protective effect of butyrate in 
limiting molecular events underlying the onset of several inflammatory-based pathologies, 
suggesting a potential clinical relevance for this compound. In particular, we have also 
showed the efficacy of its synthetic derivative N-(1-carbamoyl-2-phenyl-ethyl) butyramide 
or FBA, demonstrating that it could represent an alternative therapeutic option to sodium 
butyrate, sharing a comparable efficacy, but better palatability and compliance. 
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1. INTRODUCTION 
SCFAs are organic fatty acids with 1 to 6 carbon atoms and are the principal anions 
which arise from bacterial fermentation of polysaccharide, oligosaccharide, protein, 
peptide, and glycoprotein precursors in the colon [1]. Fermentation involves a variety of 
reactions and metabolic processes in the anaerobic microbial breakdown of organic matter, 
yielding metabolisable energy for microbial growth and maintenance and other metabolic 
end products for use by the host. The main end products are SCFAs together with gases 
(CO2, CH4, and H2) and heat [2]. Various data show that fecal SCFA production is in the 
order of acetate> propionate> butyrate in a molar ratio of approximately 60:20:20, 
respectively . The ratio seems to remain fairly constant , although alterations in production 
and absorption may occur with dietary changes. 
Carbohydrates are fermented by saccarolytic bacteria primarily in the proximal colon 
producing linear SCFAs, H2, and CO2 [3], and both the presence of carbohydrates in the 
colon and their fermentation can alter colonic physiology. Fermentation of proteins and 
amino acids by proteolytic bacteria yield branched SCFAs, H2, CO2, CH4, phenols, and 
amines. The primary effects of SCFAs are on colonic function as a result of their uptake 
and metabolism by colonocytes, although SCFAs are also metabolic substrates for other 
cells and tissues of the host. 
The production of SCFAs are determined by a number of factors, including the 
numbers and types of microbiota present in the colon, substrate source [4], and intestinal 
transit time [4]. A large microbiota population is present in the human colon at 1010 to 1011 
cfu/g wet weight [5], and more than 50 genera and over 400 species of bacteria have been 
identified in human feces [6]. Bacterial number, fermentation, and proliferation are highest 
in the proximal colon where substrate availability is greatest [7]. The principal site of 
colonic fermentation, therefore, is the cecum and proximal colon, whereas the distal colon 
is carbohydrate and water depleted. The total amount of SCFAs in the proximal colon is 
estimated to range from 70 to 140 mM [2, 4] and fall to 20 to 70 mM in the distal colon 
[2]. Therefore, the pH is lowest in the proximal colon and increases distally. Samples at 
various sites taken from patients with colonostomies indicate a decline in SCFA levels 
along the colon [2]. Specific species such as Bifidobacteria and Lactobacilli have been 
associated with improved health, resulting in the current use of probiotics, the delivery of 
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specific bacteria to the colon and prebiotics utility, or the administration of dietary 
components that promote the growth of specific bacteria with defined metabolic functions. 
The production of SCFAs are also determined by the substrate source where dietary intake 
is the most important variable. Non-digestible food components are a source of substrate 
for fermentation by anerobic colonic microbiota, because they are resistant to hydrolysis 
and digestion in the stomach and small intestine and eventually enter the colon for 
fermentation. Neither total SCFA nor the individual acids in the distal colon are predictive 
of those found proximally [8, 9]. SCFA availability in the distal colon is dynamic as water 
absorption and loss of digestive material alter availability of SCFAs independent of rates 
of production. Total SCFA and regional differences in SCFA concentration are implicated 
in diseases of the colon, especially in cancer and gastrointestinal disorders, where disease 
often occurs distally. Therefore, increased SCFA production and a greater delivery of 
SCFA distally, especially butyrate, may have a role in preventing these diseases. 
SCFAs are produced from the fermentation of carbohydrates with the major source 
coming from resistant starches [10]. However, dietary fiber, unabsorbed sugars, raffinose, 
starchyose, polydextrose, and modified cellulose also represent significant sources of 
fermentable substrates in the colon [10]. It is estimated that 5% to 20% of dietary starch is 
not absorbed by the human small intestine [11]. Insoluble fibers (eg, lignins, cellulose, and 
some hemicelluloses), which are resistant to fermentation by colonic microbiota, play an 
important role in fecal bulking and may carry with them fermentable carbohydrate 
substrate, including starches and sugars [12]. Soluble fibers (eg, pectins, gums, mucilages, 
and some hemicelluloses) are more completely fermented by colonic bacteria and may 
have little effect in increasing fecal bulk. When transit and laxation are unchanged, a 
greater intake of fermentable carbohydrates will result in higher SCFA production because 
of increased substrate availability [13, 14].Concentration and excretion of SCFAs have 
been shown to be greater with feeding of some non-starch polysaccharides, such as 
partially hydrolyzed guar gum but not others such as oat bran [14]. Therefore, there are 
several factors that may affect substrate fermentability that complicate their use in human 
studies, coupled along with a limited ability to directly measure SCFA at specific sites in 
the colon. Polyfructans are fermented by colonic bacteria [15] specifically the 
Bifidobacterium species [15], which have been shown to be associated with serum low 
density lipoprotein- cholesterol (LDL-C) reduction [16]. Furthermore, fermentation end 
products of polyfructans, specifically the SCFA propionate, have been shown to decrease 
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the acetate:propionate ratio when compared with lactulose [17] and to reduce serum 
cholesterol levels. Hence, there is a potential use for polyfructans (i.e, inulin and 
oligofructose) in combination with viscous fibers (i.e, oat bran) to lower serum cholesterol. 
Such combination effects on colonic bacteria may be used to achieve a range of therapeutic 
and preventive effects. Various sources of resistant starches [13, 14] and acarbose, the 
??glycoside hydrolase inhibitor [18, 19] also raise fecal SCFAs. The SCFA increase in 
these studies have either been reported as higher concentrations, excretion or both, which 
may reflect changes in production, absorption, and intestinal transit time. 
Changes in SCFA may not be observed when significant lower amount of non-
digestible oligosaccharides are given, since it would be rapidly fermented and immediately 
absorbed in the more proximal colon [2]. Production of individual SCFAs have also been 
measured in various studies. Greater fecal excretion of butyrate and propionate have been 
observed with consumption of wheat bran compared with vegetable fiber [20]. However, 
feeding of partially hydrolyzed guar gum resulted in greater fecal excretion of all 3 major 
SCFAs, but did not change the concentration of propionate and butyrate, or decrease their 
relative contribution. Studies using resistant starch have been consistent in showing raised 
fecal butyrate [12, 14]. Starch fermentation primarily produces acetate and butyrate, 
whereas fermentation of pectin and xylan yields acetate alone as the main product. Recent 
human studies found that acute ingestion of a non-digestible monosaccharide, L-rhamnose 
(25 g), increased serum propionate without increasing acetate [21], and this effect did not 
diminish after 28 days [22]. 
Absorption of SCFAs in the cecum and the colon is a very efficient process with only 
5% to 10% excretion in the feces [23]. Two mechanisms of absorption are proposed: (1) 
diffusion of protonated SCFAs and (2) anion exchange [4]. SCFAs are rapidly absorbed in 
the colon, and this effect is associated with enhanced sodium absorption and bicarbonate 
excretion [4]. Intubation studies have shown that SCFAs are taken up from the perfused 
human large bowel in a concentration-dependent manner [24]. At least 60% of that uptake 
is by simple diffusion of protonated SCFAs involving hydration of luminal CO2, whereas 
the residue occurs by cellular uptake of ionized SCFAs involving transport of Na+ and K+ 
[25]. SCFA uptake is associated with transport of water that seems to be greater in the 
distal than in the proximal colon [26].  
Human peripheral venous blood concentrations of SCFAs are normally low, and only 
acetate is present in significant amounts [2]. However, Wolever et al., [27] measured 
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serum propionate and butyrate, and reported values of 4.5 to 6.6 mmol/L and 2.2 to 3.9 
mmol/L, respectively. 
The major SCFAs: acetate, propionate, and butyrate are absorbed at comparable rates 
in different regions of the colon [24]. Once absorbed, SCFAs are metabolized at 3 major 
sites in the body: (1) cells of the ceco-colonic epithelium that use butyrate as a major 
substrate for maintenance-energy producing pathways; (2) liver cells that metabolize 
residual butyrate with propionate used for gluconeogenesis and 50% to 70% of acetate also 
taken up by the liver; (3) muscle cells that generate energy from the oxidation of residual 
acetate. Their oxidation supplies some 60% to 70% of the energy needs of isolated 
colonocytes [28], reduces glucose oxidation [29], and spares pyruvate [30] and glutamine 
[31]. In the presence of competing substrates such as glucose and glutamine, butyrate is the 
preferred intestinal fuel [32] suggesting that a hierarchy of oxidation exists with butyrate 
apparently being oxidized more in the proximal than in the distal colon [2]. 
The role of SCFAs has expanded to include their role as nutrients for the colonic 
epithelium, as modulators of colonic and intracellular pH, cell volume, and other functions 
associated with ion transport, and as regulators of proliferation, differentiation, and gene 
expression [4]. Increases in SCFAs result in decreased pH, which indirectly influences the 
composition of the colonic microbiota (i.e., it reduces potentially pathogenic Clostridia 
when pH is more acidic), decreases solubility of bile acids, increases absorption of 
minerals, and reduces the ammonia absorption by the protonic dissociation of ammonia 
and other amines (i.e., the formation of the less diffusible NH4+ compared with the 
diffusible NH3) [33]. In figure 1.1 the structural form of main SCFAs are shown. 
 
 
Figure 1.1: The chemical structures of main SCFAs. 
 
Acetate, the principal SCFA in the colon, is readily absorbed and transported to the 
liver, and therefore is less metabolized in the colon [4]. The presence of acetyl-CoA 
synthetase in the cytosol of adipose and mammary glands allow the use of acetate for 
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lipogenesis once it enters the systemic circulation. In human studies, acetate is often used 
to monitor colonic events because it is the main SCFA in the blood. Acetate is the primary 
substrate for cholesterol synthesis. Subjects given rectal infusions of acetate and propionate 
showed a dose-dependent increase in serum total cholesterol and triglyceride levels, 
providing indirect evidence that these SCFAs are utilized for lipid synthesis [34]. 
However, the methodology used in this study may have resulted in non-physiologic levels 
of acetyl-CoA from the rapid uptake of acetate. This may have diverted SCFA to lipid 
synthesis rather than oxidation [35]. It is possible that substrate-dependent SCFA produced 
by fermentation inhibits cholesterol synthesis [36]. However, uniform agreement has not 
been reached on the effect of increased colonic fermentation on lipid metabolism, because 
the possibility exists that different substrates may produce different effects [34]. However, 
results from human studies have been inconsistent. One-week intakes of 2.7 g sodium 
propionate taken as a capsule [37] did not affect serum lipids. Only one study showed that 
5.4 g of propionate given daily for 2 weeks lowered LDL-C and total cholesterol in 
subjects with total cholesterol>5.5 mmol/L [18]. Studies using rectal infusions indicated 
that 180 mmol of propionate did not affect serum lipids or triglycerides in healthy young 
men and women. However, when 60 mmol of propionate was infused with 180 mmol of 
acetate, free fatty acids decreased by an additional 10% and acetate, when given alone, did 
not increase total and LDL-Cholesterol [38]. Therefore, it still seems possible that one of 
the determinants of the actions of propionate on serum lipids is the ratio of propionate to 
acetate [39, 40]. 
Propionate is produced via 2 main pathways: (1) fixation of CO2 to form succinate, 
which is subsequently decarboxylated (the ‘‘dicarboxylic acid pathway’’); (2) from lactate 
and acrylate (the ‘‘acrylate pathway’’) . Propionate is a substrate for hepatic 
gluconeogenesis and has been reported to inhibit cholesterol synthesis in hepatic tissue 
[37]. However, propionate seems to have two competing and opposite effects on 
gluconeogenesis. It is both a substrate for gluconeogenesis and an inhibitor of 
gluconeogenesis. Propionate enters in the Krebs cycle at level of succinyl CoA. The 
inhibiting effect of propionate on gluconeogenesis may be related to its metabolic 
intermediaries, methylmalonyl CoA and succinyl CoA, which are specific inhibitors of 
pyruvate carboxylase. Propionate enhances glycolysis, probably by depleting hepatic 
citrate, which is an important metabolic inhibitor of phosphofructokinase. Propionate may 
also influence hepatic glucose metabolism indirectly by lowering the plasma fatty acid 
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concentration, which is itself known to be closely related to the actual rate of 
gluconeogenesis [41]. 
The majority of our knowledge about the nutritional fate of propionate comes from 
studies in ruminants. However, propionate metabolism in humans is less well understood. 
In humans, propionate may also have systemic effects, specifically a hypolipidemic action. 
Observations in animals suggest that propionate inhibits cholesterol synthesis by inhibiting 
both 3-hydroxy-3-methylglutaryl- CoA synthase and 3-hydroxy-3-methylglutaryl-CoA 
reductase [42]. As previously mentioned, polyfructans are bifidogenic and decrease the 
acetate: propionate ratio, both of which are associated with reductions in serum lipids. The 
use of polyfructans (eg, Neosugar, inulin) in individuals with Type 2 diabetes mellitus (8 
g/d) [43] and hyperlipidemia (18 g/d) [44] resulted in cholesterol reductions. However, no 
hypolipidemic effect (20 g/d) was observed in healthy subjects [17]. This inconsistency in 
human studies, in contrast to animal experiments, may be related to specie differences or 
pathological status. A number of mechanisms have been suggested to be responsible for 
the observed lipid lowering effect, with increased propionate production being one of the 
possible mechanisms of action. Increased production of propionate, through fermentation, 
may inhibit hepatic cholesterol synthesis [38, 39]. This has been supported in experimental 
studies with hyperlipidemic animals [36] but not supported in other animal studies [45]. 
 Currently, there are limited human experimental data that have quantified the 
synthesis of acetate and propionate with use of prebiotics. Propionate is better absorbed in 
the human colon than acetate [46], and studies in ruminant mucosa show that propionate is 
activated to its coenzyme A derivative (a step required for its oxidation) to a greater extent 
than acetate. The liver extracts 90% of propionate, as opposed to 75% of acetate, during a 
single pass [28] and colon infusions of equal amounts of acetate and propionate suggest 
that the amount of colonic propionate reaching peripheral blood is only 25% of the amount 
of total colonic acetate. 
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2. BUTYRATE 
 
 Butyrate is the preferred fuel of the colonic epithelial cells, which plays a pivotal 
role in regulation of cell proliferation and differentiation [2]. It is the most important SCFA 
in colonocyte metabolism, since 70% to 90% of butyrate is metabolized by these cells [4]. 
Butyrate is used preferentially over propionate and acetate in a ratio of 90:30:50 [4], and is 
preferred over glucose or glutamine supplied by blood [47]. Butyrate oxidation has been 
shown to make up more than 70% of the oxygen consumed by human colonic tissue.  
 Sodium butyrate exerts an anti-proliferative activity on many cell types, and there 
are evidence from in vivo and in vitro studies, that have demonstrated preventive effects of 
butyrate on colon adenoma development and cancer [48]. Acetate and propionate have also 
been shown to induce apoptosis in colorectal tumor cell lines, but to a much lesser extent 
than butyrate [49]. Butyrate also stimulates immunogenicity of cancer cells [50]. Currently, 
the mechanisms of action of butyrate in relation to colon cancer are not clearly defined.  
 The drop in colonic pH caused by accumulation of SCFAs decrease the solubility 
of free bile acids, which may decrease the potential tumor promoter activity of secondary 
bile acids [51]. Furthermore, increased colonic acidification (pH below 6 to 6.5) may 
inhibit colonic bacterial enzyme 7 α-dehydroxylase, which degrades primary bile acids to 
secondary bile acids [52]. In addition, decreased colonic pH increases the availability of 
calcium for binding to free bile acids and fatty acids [53]. In vitro and in vivo studies have 
shown that butyrate is the preferred energy substrate and stimulates cell proliferation in 
normal colonocytes [32], yet it suppresses proliferation of colon adenocarcinoma cells. 
 This observed inconsistency has been termed the ‘‘butyrate paradox’’[54]. This 
discrepancy may be explained by differences between in vitro and in vivo environments, 
the timing of butyrate administration in relation to the stage of cancer development, the 
amount of butyrate administered, the source of butyrate (i.e., different dietary fibers), and 
interaction with dietary fat [54].  
 The ratio of SCFA concentrations in the colonic lumen is about 60% acetate, 25% 
propionate, and 15% butyrate. As a result of increasing concentrations of acidic 
fermentation products, the luminal pH in the proximal colon is lower. This pH seems to 
boost the formation of butyrate, as mildly acidic pH values allow butyrate-producing 
bacteria to compete against Gram-negative carbohydrate-utilizing bacteria, such as 
13 
 
Bacteroides spp. [55]. The ability to produce butyrate is widely distributed among the 
Gram-positive anaerobic bacteria that inhabit the human colon (Figure 2.1). Butyrate-
producing bacteria represent a functional group, rather than a coherent phylogenetic group. 
Numerically, two of the most important groups of butyrate producers appear to be 
Faecalibacterium prausnitzii, which belongs to the Clostridium leptum (or Clostridial 
cluster IV) cluster, and Eubacterium rectale/Roseburia spp., which belongs to the 
Clostridium coccoides (or clostridial cluster XIVa) cluster of Firmicute bacteria [56]. As 
previously described, butyrate is the major energy source for colonocytes and is involved 
in the maintenance of colonic mucosal health [57]. Recently several intestinal and extra-
intestinal effects of butyrate have been demonstrated [58, 59]. Butyrate has been studied 
for its role in nourishing the colonic mucosa and in the prevention of cancer of the colon, 
by promoting cell differentiation, cell-cycle arrest and apoptosis of transformed 
colonocytes; inhibiting the enzyme histone deacetylase and decreasing the transformation 
of primary to secondary bile acids as a result of colonic acidification. Therefore, a greater 
increase in SCFA production and potentially a greater delivery of SCFA, specifically 
butyrate, to the distal colon may result in a protective effect. 
Butyrate can interact with GPR43 which is a G-protein-coupled receptor expressed in 
colonic epithelium, adipose tissue and immune cells [60]. GPR43 together with GPR109A 
are considered the main butyrate targets involved in suppression of colonic inflammation 
and carcinogenesis [61]. Moreover, butyrate modulates histone acetylation, as histone 
deacetylase (HDAC) inhibitor, and alters host epigenome, leading to its epigenetic 
mechanism [58, 59]. 
 
Figure 2.1. Production and absorption of SCFAs along the colon. 
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 Butyrate derivatives 
 Providing butyrate can be challenging for several reasons, including short 
metabolic half-life, toxicity, and patient intolerance [62]. Butyrate has been provided via 
several routes: intravenously, rectally as enemas, and orally. There are limitations to 
providing butyrate intravenously (500 mg/kg body weight) in that large volumes are 
required, and the metabolic half-life is very short, with blood levels peaking about 6 
minutes after delivery [63]. Providing higher rates of intravenous (IV) butyrate infusion is 
undesirable due to risk of toxicity from sodium overload. Rectal enemas (100 mmol/L) 
have been successful in reversing negative gastrointestinal (GI) effects in patients with 
inflammatory bowel disease; however, this mode of delivery lends to very poor patient 
compliance [63]. Tributyrin overcomes many of the problems of the parent compound. 
Tributyrin delivered orally in animals has a plasma half-life of 40 minutes [64]. In humans, 
oral delivery provided once daily for 3 weeks was without severe toxicity, and peak plasma 
butyrate concentrations occurred between 0.25 and 3 hours after dose and ranged from 0–
0.45 mM, which is near those found to be effective in vitro (0.5–1 mM) [65]. 
Butyric acid is considered a promising bioactive food compound and has been used in 
clinical trials; however, its short half-life considerably restricts its therapeutic application. 
A butyric acid pro-drug Tributyrin (TB), is present in milk fat and honey, and shows a 
more favorable pharmacokinetic properties than butyric acid. Moreover  its oral 
administration is also better tolerated. In in vitro and in vivo studies have shown that TB 
acts on multiple anticancer cellular and molecular targets [66]. TB induces apoptosis and 
cell differentiation and modulates epigenetic mechanisms. Due to its anti-carcinogenic 
potential and low toxicity, strategies as lipid emulsions, nanoparticles, or structured lipids 
containing TB are currently being developed to improve its organoleptic characteristics 
and bioavailability. Therefore, additional preclinical and clinical studies should be 
performed using TB to elucidate its molecular targets and anti-carcinogenic potential. 
Moreover, another butyrate derivative is inhibitor of HDAC, sodium phenylbutyrate, an 
aromatic fatty acid that is converted/ oxidized in vivo into phenylacetate (PAA) by b-
oxidation [67]. In humans the so formed PAA is eliminated by conjugation with glutamine 
to form phenacetylglutamine, which is excreted in the urine. This metabolic pathway is the 
mechanism by which phenylbutyrate acts as an ammonia scavenger in patients with urea 
cycle disorders (UCDs) and hyperammonemia [68]. In vitro, phenylbutyrate shows the 
ability to induce differentiation by various mechanisms [69], and the US FDA has 
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approved its clinical use in patients with hyperammonemia. Phenylbutyrate therapy for 
infants, children, and adults with UCD, which leads to nitrogen accumulation in the form 
of ammonia, must be undertaken daily and lifelong, and it is generally well tolerated and 
associated with improvements in ammonia and liver function [70]. Phenylbutyrate is 
relatively stable, with a 0.8–1 hour half-life in human serum. It has been shown that 
phenylbutyrate is able to lower very-long-chain fatty acid levels in the brain of mice with 
x-linked adrenoleukodystrophy, suggesting that phenylbutyrate can cross the blood-brain 
barrier [71]. 
 
 N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA): a new butyrate 
derivative 
In our laboratory it was synthesized a stable amide acid of butyric acid with the amino 
acid phenylalanine (N-(1-carbamoyl-2-phenilethyl) butyramide, FBA), as previously 
described (Italian patent RM2008A000214; April 21, 2008). Its chemical structure is 
illustrated in figure 2.2. Briefly, 0.01 M of phenylalanine carboximide and 0.01 M 
butyroyl chloride were dissolved in 50 ml of chloroform and the resulting mixture was left 
to react at room temperature for 24 h. The mixture, evaporated in vacuo, yields a solid 
white-color residue, that was washed with a 1% sodium bicarbonate solution. The aqueous 
bicarbonate solution was extracted twice with an equal volume of ethyl acetate to recover 
an additional fraction of the mixture of derivatives. To isolate the single components, the 
mixture was treated and processed chromatographically on a silica gel column, using 
dichloromethane as eluent. The compound was re-crystallised with a mixture of 
chloroform/n-hexane 1:1(v: v), obtaining a final yield equal to or greater than 50%. FBA is 
a solid, poorly hygroscopic, easily weighable form, stable to acids and capable of releasing 
butyric acid at small and large bowel level in a constant manner over time.  
This product, referred to toxicity studies performed in our laboratory, demonstrated a 
toxicological profile similar to that of butyric acid, has compared to the latter, excellent 
physic-chemical characteristics. In fact, the product is in solid form, slightly hygroscopic, 
easy to be weighed, stable to acids and alkalis and it is able to release in a constant way in 
time butyric acid in the small intestine and colon. A particularly important aspect of FBA 
is that it doesn’t have the unpleasant rancid odor of butyrate and is practically tasteless. 
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Moreover, the solubility of FBA in water is satisfactory in that it produces clear solutions 
up to the concentration of 0.1 M and suspensions for higher concentrations. 
 FBA has been studied in a model of non alcoholic fatty liver disease and the use of 
this derivative prevented the development of insulin resistance and decreased pro-
inflammatory parameters in the liver, through the suppression of the Toll receptors and the 
activation of NF-kB [72]. 
 
      
 
Figure 2.2. Chemical structure of N-(1-carbamoyl-2-phenilethyl) butyramide, FBA. 
 
 GPR43 and GPR41 as key receptors for SCFAs 
G-protein-coupled receptors (GPCRs) are seven-transmembrane (7TM) receptors 
that mediate cellular responses to the majority of hormones and neurotransmitters, and are 
therefore attractive targets for drug discovery [73]. Free fatty acids (FFAs) have long been 
considered as key signalling molecules in numerous physiological and pathological 
processes. The identification of a family of GPCRs that bind FFAs has highlighted new 
potential mechanisms of action for FFAs in health and disease [74]. Among these FFAs 
receptors, GPR43 is present in a large variety of tissues, including adipose tissue, 
inflammatory cells, and gastrointestinal (GI) tract and it is activated by SCFAs [75, 76]. 
The identification of these endogenous ligands of GPR43 has led the scientific community 
to propose a new appellation for GPR43, namely FFA2 or FFAR2 [74, 77]. SCFAs bind 
GPR43 in the following rank order of potency: propionate > acetate=butyrate > valerate > 
formate [75, 77]. Importantly, SCFAs also activate another receptor of the same family, 
GPR41, with propionate and butyrate being the most potent agonists [75, 78]. Both 
receptors can couple to G?i/0 resulting in inhibition of the adenylate cyclase pathway, but 
only GPR43 is also able to couple to G?q, thus leading to activation of the phospholipase C 
(PLC) pathway and increased intracellular calcium levels [75, 78]. GPR41 and GPR43 
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bind the same family of ligands (SCFAs), exhibit some overlapping expression, and 
partially share signalling pathways (G?i/0). Furthermore, both receptors represent 
potentially interesting targets for drug discovery.  
 
GPR43 and GI tract functions 
Since GPR43 is largely expressed throughout the gut, several authors have suggested 
that some effects of SCFAs could be GPR43-dependent. In 2006, Karaki et al. 
demonstrated that GPR43 was expressed in rat distal ileum and colon. Interestingly, 
peptide YY (PYY)-containing enteroendocrine L cells were immunoreactive for GPR43, 
whereas 5-hydroxytryptamine (5-HT) immunoreactive mast cells coexpressed GPR43 [79]. 
PYY is a satietogenic peptide that inhibits upper GI motility and SCFAs have been shown 
to induce its release in the blood [80]. Therefore, SCFAs might stimulate L cells to release 
PYY via GPR43 activation, thus slowing intestinal transit. GPR43 expression in 
enteroendocrine L cells was observed likewise in the human colon [81]. SCFAs also exert 
physiological effects on colonic motility and secretion via 5-HT release [82] and Karaki et 
al. proposed this might be attributable to the activation of GPR43 on 5-HT-containing mast 
cells [79]. The presence of GPR43 throughout the rat gut, with the lowest mRNA levels 
observed in the esophagus and stomach and the highest levels detected in the colon, was 
also confirmed [83]. 
Glucagon-like peptide 1 (GLP-1) is another gut hormone released by enteroendocrine L 
cells that is involved in the control of intestinal function and glucose metabolism [84]. 
SCFA infusion was shown to induce plasma GLP-1 release in animals and humans [85]. 
Interestingly, co-localization of GPR43 and GLP-1 in enteroendocrine L cells was 
demonstrated in both rat and human colon and terminal ileum [86]. In rodents, 
supplementation with fermentable carbohydrates increased GLP-1 production and the 
density of GPR43/GLP-1-positive enteroendocrine L cells in the proximal colon [86]. 
Therefore, a higher colonic production of SCFAs following dietary fiber fermentation 
increase GLP-1 secretion, via GPR43 activation. This hypothesis has been recently 
confirmed by Tolhurst et al. [87]. The SCFA-triggered secretion of GLP-1 was almost 
completely abolished in primary colonic cultures from GPR43 KO mice but was also 
reduced, to a lesser extent, in mice lacking GPR41. GPR43-deficient mice had 
significantly reduced colonic GLP-1 protein content. Moreover, basal and glucose-
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stimulated levels of active GLP-1 were reduced in both GPR43 and GPR41 KO mice. 
These effects were associated with impaired glucose tolerance. Even if mice lacking 
GPR43 also exhibited decreased colonic expression of GPR41, a dominant role for GPR43 
in SCFA-induced L cell activation was suggested based on the prevailing involvement of 
G?q coupled pathways in this process (figure 2.3) [87]. These results reveal again the 
difficulty to generate GPR43 KO mice without affecting GPR41, thus introducing 
uncertainties about their interpretation. Studies conducted in germ-free (GF) mice 
highlighted a potential link between gut microbiota and the expression of FFA receptors. 
The conventionalization (colonization by normal mouse microbiota) of GF mice increased 
adiposity and decreased the expression of GPR41 and GPR43 in the distal small intestine 
[88]. However, another study reported that GF mice exhibited decreased intestinal 
expression of GPR43, GPR41, PYY, and GLP-1 as compared with conventional mice. It is 
worth noting that the expression of GPR43 and GPR41 was differentially affected in GF 
mice, with a 10% and 70% decrease, respectively. This was associated with lower levels of 
circulating PYY [89]. Overall, these results suggest that gut microbiota can influence the 
intestinal expression of SCFA receptors and the secretion of gut peptides, but further 
studies are needed to elucidate the underlying mechanisms. 
 
Figure 2.3. Location and physiological functions of G-protein-coupled receptor 43 (GPR43). Studies in rodents have highlighted 
that SCFAs bind to GPR43 to exert several physiological actions. GPR43 activation on intestinal enteroendocrine cells (in pink) induces 
the production of PYY and GLP-1. PYY inhibits intestinal transit and appetite, whereas GLP-1 is anorexigenic and stimulates insulin 
secretion. In mice, GPR43 expression increases during adipogenesis and SCFAs stimulate adipocyte differentiation (fibroblast in 
orange). Through their binding to GPR43, SCFAs also inhibit lipolysis in mature adipocytes (in yellow). Finally, SCFAs induce 
chemotaxis of neutrophils (in blue) through GPR43 activation. Abbreviations: TG, triglycerides; FFAs, free fatty acids. Image from : 
Bindels, Dewulf, Delzenne. GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci. 2013 
Apr;34(4):226-32. doi: 10.1016/j.tips.2013.02.002. Epub 2013 Mar 13. 
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GPR43 and inflammation 
SCFAs have long been known to modulate the production of pro- and anti-
inflammatory mediators [90]. For instance, production of prostaglandin E2 is reduced by 
SCFAs. This effect can be inhibited by pertussis toxin, suggesting the involvement of a G-
protein-mediated signalling [91]. The formal proof of GPR43 involvement in the 
management of inflammation was simultaneously provided by two research teams. They 
both established the contribution of GPR43 to the recruitment of immune cells [6,48], and 
this observation was further confirmed by others [92]. However, these studies showed 
divergent findings on the potential impact of GPR43 in inflammatory diseases. Maslowski 
et al., [76] demonstrated that stimulation of GPR43 by acetate allowed resolution of colitis-
related inflammatory response. GPR43 KO mice showed exacerbated or unresolved 
inflammation in cases of acute and chronic colitis, arthritis, and asthma. This could be 
related to increased immune cell recruitment [76]. By contrast, Sina et al. reported that, in 
an acute colitis model, GPR43 KO mice showed an increased mortality compared with 
control mice, despite reduced immune cell recruitment, decreased colonic inflammation, 
and attenuated colonic tissue damage. The increased mortality was attributed to septic 
complication. In a chronic colitis model, GPR43 deficiency led to reduced colonic 
inflammation, without any sign of sepsis and any lethality. The authors pointed out the 
bipotential pathophysiological role of immune cells at the intestinal level, being a 
protective factor against acute bacterial transmigration, but having a detrimental role in 
chronic inflammatory responses [93]. Clearly, GPR43 is involved in the SCFA-induced 
neutrophil chemotaxis in mice (figure 2.3) [76, 92]. However, demonstrating GPR43 
contribution to human neutrophil chemotaxis remains to be accomplished. Interestingly, 
GLPG0974, an orally available small GPR43 inhibitor from Galapagos with undisclosed 
structure, has been claimed to reduce neutrophil migration. GLPG0974 is currently being 
tested in a second Phase I study and results are expected in early 2013 (ClinicalTrials.gov; 
identifier: NCT01721980). The global role of GPR43 in inflammatory conditions needs to 
be clarified before ruling on the therapeutic potential of GPR43 in this context. The 
dualistic action of SCFAs, being anti-inflammatory while recruiting neutrophils, might be 
one of the keys to full understanding of how SCFAs and GPR43 manage inflammation. 
Importantly, a comparison of several studies highlights that the biological and molecular 
responses to SCFAs differ in the several type of immune cell [92]. This might be consistent 
with the various temporal roles of these cells in an inflammatory response [91]. Therefore, 
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the different molecular pathways downstream of GPR43 remain to be elucidated. Finally, 
Inulin-type fructans (ITF) prebiotic feeding can control inflammation in rodent models of 
colitis, obesity, diabetes, and leukemia [94, 95]. It is possible to postulate that prebiotics, 
through their fermentation into SCFAs, might exert some of their anti-inflammatory effects 
in a GPR43-dependent manner, this hypothesis need to be confirmed. 
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3. EFFECTS OF BUTYRATE AT INTESTINAL LEVEL 
 
Effects on inflammatory process and oxidative stress 
Butyrate plays a role as an anti-inflammatory agent, primarily via inhibition of NF-
κB activation in human colonic epithelial cells [96], which may result from the inhibition 
of histone deacetylase (HDAC). NF-κB regulates many cellular genes involved in early 
immune inflammatory responses, including IL-1?, TNF-α, IL-2, IL-6, IL-8, IL-12, iNOS, 
COX-2, intercellular adhesion molecule-1 (ICAM-1), vascular cellular adhesion molecule-
1 (VCAM-1), T cell receptor-α (TCR-α), and MHC class II molecules [97]. The activity of 
NF-κB is frequently dysregulated in colon cancer [98] and in IBDs, such as ulcerative 
colitis (UC) and Crohn’s disease (CD) [99]. In CD patients, butyrate decreases pro-
inflammatory cytokine expression via inhibition of NF-κB activation and IκBα degradation 
[99]. The upregulation of PPAR-γ and the inhibition of IFN-γ signaling, are another two of 
butyrate’s anti-inflammatory effects [100]. Butyrate can act on immune cells through 
GPR41 (or FFA3) and GPR43 (or FFA2), which are both expressed on immune cells, 
including polymorphonuclear cells, suggesting that butyrate might be involved in the 
activation of leucocytes [101]. The possible immune-modulatory functions of SCFAs are 
highlighted by a recent study on GPR43-/- mice. These mice exhibit aggravated 
inflammation, related to increased production of inflammatory mediators and increased 
immune cell recruitment [93]. Most clinical studies analyzing the effects of butyrate on 
inflammatory status focused on UC patients. Hallert et al. [102] instructed 22 patients with 
quiescent UC to add 60 g oat bran (corresponding to 20 g dietary fiber) to their daily diet. 
Four weeks of this treatment resulted in a significant increase of fecal butyrate 
concentration and in a significant improvement of abdominal symptoms. In a double blind, 
placebo-controlled multicenter trial, Vernia et al., [103] treated 51 patients with active 
distal UC with rectal enemas containing either 5-aminosalicylic acid (5-ASA) or 5-ASA 
plus sodium butyrate (80 mmol/L, twice a day). The combined treatment with topical 5-
ASA plus sodium butyrate significantly improved the disease activity score more than 5-
ASA alone. These and other intervention studies [104] suggested that the luminal 
administration of butyrate or stimulation of luminal butyrate production by the ingestion of 
dietary fiber results in an amelioration of the inflammation and symptoms in UC patients. 
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Numerous studies have reported that butyrate metabolism is impaired in intestinal inflamed 
mucosa of patients with IBD. Recent data show that butyrate deficiency results from the 
reduction of butyrate uptake by the inflamed mucosa through downregulation of 
monocarboxylate transporter isoform 1 (MCT1). The concomitant induction of the glucose 
transporter GLUT1 suggests that inflammation could induce a metabolic switch from 
butyrate to glucose oxidation. Butyrate transport deficiency is expected to have clinical 
consequences. Particularly, the reduction of the intracellular availability of butyrate in 
colonocytes may decrease its protective effects toward cancer in IBD patients [105]. 
Limited evidence from pre-clinical studies shows that oxidative stress in the colonic 
mucosa can be modulated by butyrate. Oxidative stress is involved in both inflammation 
[106] and the process of initiation and progression of carcinogenesis [107]. During 
oxidative stress there is an imbalance between the generation of reactive oxygen species 
(ROS) and the antioxidant defense mechanisms, leading to a cascade of reactions in which 
lipids, proteins, and/or DNA may get damaged. In healthy humans, it has been 
demonstrated that locally administered butyrate in physiological concentrations increased 
the antioxidant GSH and possibly decreased ROS production, as indicated by a decreased 
uric acid production [108]. As the human colon is continuously exposed to a variety of 
toxic stimuli, enhanced butyrate production in the colon could result in an enhanced 
resistance against toxic stimuli, thus improving the barrier function. This might be relevant 
for the treatment of gastrointestinal disorders, such as post-infectious irritable bowel 
syndrome (IBS), microscopic colitis, IBDs, and diversion colitis. 
 
Butyrate and intestinal epithelial permeability 
Intestinal epithelial permeability has been widely studied as an important parameter 
of the intestinal defense barrier. Under normal conditions, the epithelium provides a highly 
selective barrier that prevents the passage of toxic and pro-inflammatory molecules from 
the external milieu into the submucosa and systemic circulation. Macromolecules pass the 
epithelial barrier mainly via the paracellular route for which tight junctions are the rate-
limiting structures [109]. Increased permeability, indicating impaired epithelial barrier 
function, is thought to be involved in the pathophysiology of several gastrointestinal 
inflammatory diseases, but can either be a cause or a consequence of inflammation [110]. 
Several studies have assessed the effects of butyrate on intestinal permeability in vitro as 
23 
 
well as ex vivo. At low concentrations, butyrate (up to 2 mM) induces a concentration-
dependent reversible decrease in permeability in a Caco-2 and HT-29 cell lines [111]. This 
decrease in permeability may be related to the butyrate associated increased expression of 
tight junction proteins observed in different cultured cell lines, but this effect was shown to 
be cell type dependent [112]. At higher concentrations (8 mM), however, butyrate 
increased the permeability in a Caco-2 cell line [111]. An ex vivo study, using adult rat 
distal colon mucosa mounted in an Ussing chamber, demonstrated that acute exposure to 
butyrate at a concentration of 10 mM, but not 1 or 5 mM increased paracellular 
permeability in rat colon [113]. This has also been demonstrated in rats fed a diet-
containing fermentable FOS. The rapid bacterial fermentation of FOS led to accumulation 
of high concentrations of SCFAs that increased intestinal permeability and was associated 
with increased translocation of Salmonella [114]. However, in humans, daily FOS 
supplementation of 20 g did not increase intestinal permeability [115]. It can be concluded 
that the effect of butyrate on intestinal permeability depends on its concentration and on 
the model system or species used. The effects of butyrate at different concentrations 
remain to be evaluated in in vivo studies. 
 
Effects on transepithelial ion transport 
Potentially, SCFAs are absorbed by each intestinal segment, as demonstrated in 
animal models and human volunteers. The colonocytes absorb butyrate and other SCFAs 
through different mechanisms of apical membrane SCFA uptake, including non-ionic 
diffusion, SCFA/HCO3- exchange, and active transport by SCFA transporters. The 
transport protein involved are MCT1, which is coupled to a transmembrane H+-gradient, 
and SLC5A8, which is Na+-coupled co-transporter [116]. The absorption of these fatty 
acids has a significant impact on the absorption of NaCl and, generally, on the electrolyte 
balance [117]. In particular, butyrate is able to exert a powerful proabsorptive stimulus on 
intestinal NaCl transport and an anti-secretory effect towards Cl- secretion. The powerful 
regulatory pro-absorptive/anti-secretory effects induced by butyrate on the trans-epithelial 
ion transport occurs through several mechanisms: (1) stimulation of NaCl absorption by 
the action of two coupled transport systems on the intestinal brush border: Cl-/HCO3- and 
Na+/H+ and Cl-/butyrate and Na+/H+; and (2) inhibition of Cl- secretion by blocking the 
activity of the co-transporter Na+-K+-2Cl- (NKCC1) on the enterocyte basolateral 
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membrane. In vitro studies have shown that butyrate has an inhibitory effect on Cl- 
secretion induced by prostaglandin E2, cholera toxin, and phosphocholine. This effect is 
due to reduced production of intracellular cAMP secondary to the expression and 
regulation of adenylate cyclase [116]. Comparison studies showed that the pro-absorptive 
and anti-secretory effects of butyrate are significantly higher than those of all other SCFAs 
[117]. Clinical studies in children with acute diarrhea caused by V. cholerae showed a 
reduction in stool volume and a more rapid recovery in patients who received oral 
rehydration therapy in addition to resistant starch, a precursor of butyrate, in the diet [118]. 
These results were confirmed in other forms of infectious diarrhea in children and in 
animal models studies [55]. Moreover, butyrate therapy is beneficial in patients affected by 
Congenital Chloride Diarrhea (CLD) [56]. This rare genetic disease is caused by mutations 
in the gene encoding the solute-linked carrier family 26-member A3 (SLC26A3) protein, 
which acts as a plasma membrane anion exchanger for Cl- and HCO3- [119]. The 
mechanism underlying this therapeutic effect could be related, at least in part, to 
stimulation of the Cl-/butyrate exchanger activity [56]. It is also possible that butyrate 
could reduce mistrafficking or misfolding of the SLC26A3 protein, as demonstrated for 
other molecules involved in transepithelial ion transport [120]. Alternatively, butyrate may 
enhance gene expression: the SLC26A3 gene contains a 290-bp region between residues -
398 and -688 that is crucial for high-level transcriptional activation induced by butyrate. 
This may explain the variable response of patients affected by CLD to butyrate [57]. In 
fact, depending on the patient’s genotype, mutations in the above-mentioned regulatory 
regions of the SLC26A3 gene could affect the gene transcription rate. It is also conceivable 
that other channels could be involved in the therapeutic effect of butyrate in CLD. 
 
Effects on visceral perception and intestinal motility 
Little is known about the environmental and nutritional regulation of the enteric 
nervous system (ENS), which controls gastrointestinal motility. Butyrate regulates colonic 
mucosa homeostasis and can modulate neuronal excitability. Soret et al., [121] investigated 
the effects of butyrate on the ENS and colonic motility, and showed, in vivo and in vitro, 
that butyrate significantly increased the proportion of choline acetyltransferase (ChAT), 
but not neuronal nitric oxide synthase (nNOS) immunoreactive myenteric neurons. 
Butyrate increases the cholinergic-mediated colonic circular muscle contractile response ex 
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vivo. The authors suggest that butyrate might be used, along with nutritional approaches, to 
treat various gastrointestinal motility disorders associated with inhibition of colonic transit. 
A recent study by Vanhoutvin et al., [122] shows that intraluminal administration of a 
physiologically relevant dose (50 to 100 mmol/L-) of butyrate into the distal colon 
increases compliance and decreases pain, urge, and discomfort measured with a rectal 
barostat procedure in healthy subjects. This study suggests a potential beneficial effect of 
butyrate in disorders that are associated with visceral hypersensitivity, such as IBS and 
infantile colics, and provides a basis for future trials with dietary modulation resulting in 
intracolonic butyrate production in both healthy and IBS subjects. The decrease in visceral 
perception induced by butyrate treatment could be due to an increased 5-HT release, as 
previously suggested by others [123]. Another possible mechanism by which butyrate 
could affect visceral perception is the previous reported inhibition of histone deacetylase. 
In fact, Chen et al., [124] showed that these inhibitors induce microglyal apoptosis and 
attenuate inflammation-induced neurotoxicity in rats, which may affect visceral perception. 
Butyrate has been reported to induce enhancement of colonic motility via the release of 5-
HT [125]. In functional studies, butyrate and propionate induced phasic and tonic 
contractions in rat colonic circular muscle. The dose-dependent contractile effect occurred 
only when SCFAs were applied on the mucosal side and disappeared in mucosal free 
preparations, suggesting the presence of sensory mechanisms near the epithelium [82]. 
The effects of butyrate at intestinal levels are resumed in schematic figure 3.1. 
 
 
Figure 3.1. Effects of butyrate at intestinal level. 
 
Effects on non-specific intestinal defense mechanisms 
Besides the effects of butyrate on carcinogenesis, inflammation and oxidative stress, 
butyrate has been shown to affect several components of the colonic defense barrier 
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leading to enhanced protection against luminal antigens. One important component of this 
barrier is the mucous layer covering the epithelial lining consisting of mainly mucin 
glycoproteins and trefoil factors (ITF or TFF3). Mucin glycoproteins are classified into 
neutral and acidic subtypes and the latter category further includes sulfomucins and 
sialomucins. Sulphated mucins are generally considered to be more resistant to bacterial 
degradation [126]. Several epithelial mucin (MUC) genes have been identified in humans, 
of which MUC2 is predominantly expressed in the human colon [127]. Alterations in 
goblet cell function, composition and thickness of the intestinal mucous layer have been 
found in several intestinal disorders. For example, a reduced mucous thickness and a 
decreased MUC2 production have been reported in UC patients [128]. In in vitro studies, 
butyrate increased the MUC2 gene expression in specific cell lines [129, 130]. In addition, 
0.1–1 mM butyrate administered to human colonic biopsy specimens ex vivo stimulated 
mucin synthesis [131]. Luminal butyrate administration of 5 mM, but not 100 mM, 
increased mucous secretion in an isolated perfused rat colon [132]. In another rat study, 
caecal and faecal SCFA concentrations were found to correlate with mucous thickness. In 
humans, effects of butyrate on mucous synthesis, thickness of the mucous layer and MUC 
expression in vivo have not been reported. The effects of a number of fermentable dietary 
fibers on the mucous layer have been studied with variable results. For example, resistant 
starch increased the number of acidic mucins, but did not affect the number of goblet cells 
in rats [133]. In contrast, FOS increased the number of goblet cells in piglets [134]. In a 
human intervention study with patients with an ileo-anal pouch, inulin supplementation did 
not alter MUC2 expression or the ratio between sulfomucins and sialomucins [135]. 
Trefoil factors are mucin-associated peptides that contribute to the viscoelastic properties 
of the mucous layer. TFFs are thought to reduce the recruitment of inflammatory cells and 
to be involved in the maintenance and repair of the intestinal mucosa, although the exact 
mechanism for this effect is not yet known [136]. Intestinal trefoil factor is almost 
exclusively secreted by the intestinal goblet cells [137]. In a rat TNBS model of colitis, 
TFF3 expression was decreased during active disease, and intracolonic administration of 
butyrate increased TFF3 expression [138]. However, butyrate inhibited the expression of 
TFF3 in colon cancer cell lines and in colonic tissue of newborn rats [139]. Other 
components of the colonic defense barrier that are involved in the maintenance of the 
colonic barrier, which may be influenced by butyrate are transglutaminase, antimicrobial 
peptides and heat shock proteins (HSPs). The enzyme transglutaminase is actively 
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involved in intestinal mucosal healing and correlates with the severity of inflammation in 
UC [140]. In a rat model of colitis, butyrate restored the colonic transglutaminase levels 
[141]. Antimicrobial peptides such as cathelicidin (LL-37) and defensins, protect the 
gastrointestinal mucosa against the invasion and adherence of bacteria and thereby prevent 
infection [142]. Several in vitro studies have shown that butyrate up-regulates the 
expression of LL-37 in different colon epithelial cell lines as well as in freshly isolated 
colorectal epithelial cells [143]. HSPs confer protection against inflammation by 
suppressing the production of inflammatory modulators [144, 145]. Butyrate induced the 
expression of HSP70 and HSP25 in Caco-2 cells [145] and in rats [133, 144]. However, in 
DSS induced colitis butyrate inhibited HSP70 expression in rats. This effect was related to 
protection against the decrease in cell viability, increase in mucosal permeability and 
neutrophil infiltration in DSS colitis. It was concluded that the induction of heat shock 
response had a protective effect before an injury, whereas activation of heat shock response 
leads to cytotoxic effects after a pro-inflammatory stimulus [146]. In addition, there is 
evidence from in vitro studies with human colon cancer cell lines that butyrate is involved 
in repair after mucosal damage through an increase in the rate of cell migration. Efficient 
repair of superficial injuries and mucosal ulcers is important in maintaining and re-
establishing the epithelial barrier [147]. In conclusion, there are several lines of evidence 
suggesting that butyrate reinforces the colonic defense barrier by affecting several 
components of this barrier, such as the promotion of epithelial migration and the induction 
of mucins, TFF, transglutaminase activity, antimicrobial peptides and HSPs. However, 
most of these effects still have to be confirmed in the human studies. 
 
Effects on cell growth and differentiation 
Several epidemiological studies have supported the role of dietary fiber in the 
protection against colorectal cancer [148, 149]. Different mechanisms have been proposed 
for fiber’s cancer preventive properties: reduction in transit time of the feces in the gut, 
which reduces exposure of the mucosa to luminal carcinogens; absorption of bile acids, 
biogenic amines, bacterial toxins, and production of butyrate. Most of the anti-carcinogenic 
effects of butyrate were observed in vitro carcinoma cell lines. In these models, addition of 
butyrate led to inhibition of proliferation, induction of apoptosis, or differentiation of 
tumor cells [150]. Butyrate’s anti-carcinogenic effects are in contrast with the effects of 
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this compound in normal enterocytes. In fact, it has been shown that butyrate stimulates the 
physiological pattern of proliferation in the basal crypt in the colon, whereas it reduces the 
number and the size of aberrant crypt focus, which are the earliest detectable neoplastic 
lesions in the colon [151]. These contradictory patterns of butyrate represents the so called 
“butyrate paradox” [150]. An important mechanism by which butyrate causes biological 
effects in colon carcinoma cells is the hyperacetylation of histones by inhibiting HDAC. 
An imbalance of histone acetylation can lead to transcriptional dysregulation and silencing 
of genes that are involved in the control of cell cycle progression, differentiation, apoptosis 
and cancer development [152, 153]. In particular, in human colon cancer cell lines 
butyrate, acting as HDAC inhibitor, increases the p21 (WAF1) gene expression by 
selectively regulating the degree of acetylation of the gene-associated histones, and induces 
G1 cell cycle arrest [154]. A novel contributory mechanism to the chemopreventive effect 
of butyrate is the downregulation of the key apoptotic and angiogenesis regulator 
Neuropilin-1 (NRP-1), which has been shown to promote tumor cell migration and 
survival in colon cancer in response to vascular endothelial growth factor (VEGF) binding 
[155]. Several reports have shown that the apoptosis triggered by butyrate in vitro is 
associated with dysregulation of Bcl2 family proteins, especially up-regulation of BAK 
and downregulation of Bcl-xL [156], rather than cellular damage. A study by Thangaraju 
et al suggests a novel mode of action of butyrate in the colon involving GPR109A, a G-
protein–coupled receptor for nicotinate [157], which recognises butyrate with low affinity. 
This receptor is expressed in the normal colon on the lumenfacing apical membrane of 
colonic epithelial cells, but is silenced in colon cancer via DNA methylation. Thangaraju et 
al., [157] showed that inhibition of DNA methylation in colon cancer cells induces 
GPR109A expression and that activation of the receptor causes tumor cell–specific 
apoptosis. Butyrate is an inhibitor of HDAC, but apoptosis induced by activation of 
GPR109A with its ligands in colon cancer cells does not involve inhibition of histone 
deacetylation. The primary changes in this apoptotic process include downregulation of 
Bcl-2, Bcl-xL, and cyclin D1 and upregulation of death receptor pathway. Moreover, a 
recent study suggested that the protective role of dietary fiber, and its breakdown product 
butyrate, against colorectal cancer could be determined by a modulation of canonical Wnt 
signaling, a pathway constitutively activated in the majority of colorectal cancers [158]. 
Butyrate is recognized for its potential to act on secondary chemoprevention, by slowing 
growth and activating apoptosis in colon cancer cells , but it can also act on primary 
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chemoprevention. The mechanism proposed is the transcriptional up-regulation of 
detoxifying enzymes, such as glutathione-S-transferases (GSTs). This modulation of genes 
may protect cells from genotoxic carcinogens, such as H2O2 and HNE [152].  
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4. EXTRA-INTESTINAL EFFECTS OF BUTYRATE 
 
Hemoglobinopathies 
Clinical trials in patients with sickle cell disease and β-thalassemia confirmed the 
ability of butyrate to increase fetal hemoglobin (HbF) production [159, 160]. Butyrate is an 
inducer of HbF through an epigenetic regulation of fetal globin gene expression via HDAC 
inhibition, resulting in global histone hyperacetylation, including nucleosomes at the γ-
globin promoters [161]. Other experiments have shown that butyrate can cause a rapid 
increase in the association of γ-globin mRNA with ribosomes [162]. It has been 
demonstrated that activation of p38 mitogen activated protein kinases and cyclic nucleotide 
signaling pathways is associated with butyrate induction of HbF [163]. Taken together, 
these studies suggest that global histone hyperacetylation induced by HDAC inhibition is 
not the unique mechanism underlying butyrate stimulation of HbF. 
 
Genetic metabolic diseases 
Sodium phenylbutyrate 4 (4-PBA) was approved by the Food and Drug 
Administration (FDA) for use in patients with urea cycle enzyme deficiency, in which it 
acts as a scavenger of ammonia. Indeed, 4-PBA is oxidized to phenylacetate, which binds 
to glutamine and determines the urinary excretion. In patients with ornithine 
transcarbamylase deficiency, the use of 4-PBA allows for better metabolic control and 
increased intake of natural protein in the diet [164]. The possible use of butyrate in the 
treatment of X-linked Adrenoleukodystrophy (X-ALD), a disorder of peroxisomes 
characterized by altered metabolism and accumulation of very long chain fatty acids, has 
also been studied. Sodium phenylbutyrate 4 induces an increase in β-oxidation of very long 
chain fatty acids and peroxisome proliferation, both in vitro on fibroblasts from patients 
with X-ALD than in vivo in X-ALD knockout mice [165]. 
 
Hypercholesterolemia 
Under normal lipidemic conditions, the liver is the most important site of cholesterol 
biosynthesis, followed by the intestine. Biosynthesis in the liver and intestine account for 
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about 15% and 10%, respectively, of the total amount of cholesterol biosynthesis each day 
[166]. In hypercholesterolemia, when cholesterol biosynthesis is suppressed in liver by 
fasting, the intestine becomes the major site of cholesterol biosynthesis, and its 
contribution can increase up to 50%. Importantly, recent evidence shows that the global 
effect of butyrate is to downregulate the expression of nine key genes involved in intestinal 
cholesterol biosynthesis, potentially inhibiting this pathway [167]. 
 
Obesity and insulin resistance 
Dietary supplementation with butyrate can prevent and treat diet-induced obesity and 
insulin resistance in mouse models. After a 5-wk treatment with butyrate, obese mice lost 
10.2% of their body weight. Consistent with the change in body weight, fat content was 
reduced by 10%. Furthermore, fasting glucose was reduced by 30%, insulin resistance was 
reduced by 50%, and intraperitoneal insulin tolerance was improved significantly by 
butyrate. The mechanism of butyrate action is related to promotion of energy expenditure 
and induction of mitochondrial function. Stimulation of peroxisome proliferator-activated 
receptor (PPAR) coactivator (PGC-1α) activity has been suggested as the molecular 
mechanism of butyrate. Activation of AMP-activated protein kinase (AMPK) and 
inhibition of histone deacetylases may contribute to the PGC-1α regulation. These data 
suggest that butyrate may have potential application in the prevention and treatment of 
metabolic syndrome in humans [168]. 
 
Butyrate and satiety 
It has been hypothesized that SCFAs produced in the large intestine also can 
influence upper gut motility and satiety [169]. Endocrine L-cells present in large 
concentrations in the colonic mucosa secrete peptides such as GLP-1, peptide YY and 
oxyntomodulin, which are involved in appetite regulation and satiety [170]. In several 
animal studies using fermentable carbohydrates such as inulin [170], lactitol [171] and 
FOS [172], an increased satiety, decreased weight gain and increased endogenous 
production of GLP-1 and ⁄ or PYY were reported. In humans, FOS increased satiety [173] 
and increased plasma GLP-1 concentrations [174]. However, lactitol did not affect plasma 
concentrations of this gut peptide [171]. The increased satiety is possibly promoted 
through the production of SCFAs. This is supported by a number of studies. Butyrate 
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increased the expression of PYY and pro-glucagon in vitro in rat epithelial cells [175] and 
increased PYY release, but not that of GLP-1, in the isolated colon of rats [176] and rabbits 
[177]. In addition, colonic SCFA infusion in rats stimulated PYY release [178]. However, 
colonic infusion with SCFAs in humans did not increase plasma levels of either PYY or 
GLP-1 [179]. Activation of the SCFA receptor GPR43 expressed in endocrine L-cells may 
play a role in this effect on satiety [81]. There is increasing evidence that the effect of 
fermentable dietary fiber on satiety is mediated through the colonic production of SCFAs. 
However, most evidence originates from rat studies, while again human evidence remains 
limited. In figure 4.1 the main intestinal SCFA receptors and transporters are shown. 
 
 
Fig. 4.1. Intestinal SCFA receptors and transporters. SCFAs are taken up by the epithelial cells by diffusion, H+ coupled transport by 
monocarboxylate transporters (MCT) or by Na+ coupled transport by SLC5A8. Other receptors that are activated by SCFA are localized 
on colonocytes, peptide YY expressing enteroendocrine cells, or different immune cells. Receptor FFAR2 is involved in neutrophil 
chemotaxis toward sources of SCFA. Image from: Schilderink, Verseijden and de Jonge. Dietary inhibitors of histone deacetylases in 
intestinal immunity and homeostasis. Front. Immunol., 01 August 2013 doi: 10.3389/fimmu.2013.00226.  
 
5. ADVERSE EFFECTS OF BUTYRATE 
 
In contrast to the wide range of positive effects of butyrate on the intestinal mucosa, 
a small number of studies have also shown some adverse effects. Two studies on rat 
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revealed that rectal administration of butyrate (8–1000 mM), dose dependently increased 
colonic visceral sensitivity [180]. However, these effects have not yet been reported in 
humans. In faeces of weaning children, low butyrate concentrations have been measured 
[181]. It has been hypothesized that overproduction or accumulation of SCFAs may be 
toxic to the intestinal mucosa of premature infants and might play a role in the 
pathogenesis of neonatal necrotizing enterocolitis. It has been demonstrated that the 
severity of mucosal injury to butyrate, measured in newborn rats, was dose dependent and 
also depended on the maturation of the intestine [139, 182]. It remains to be established 
whether luminal butyrate in premature infants can increase towards levels that are toxic for 
the intestinal mucosa [182]. In addition, as mentioned before, increased permeability and 
Salmonella translocation has been found after FOS supplementation in a study with rats, 
which may be the result of SCFA accumulation [114]. However, this was not confirmed in 
the humans [115]. 
Moreover, despite the potential benefits of SCFA as a therapeutic treatment, the 
review of Lei et al. [183] describes that SCFA, in particular propionic acid and butyric 
acid, are implicated in non genetically related Autism Spectrum Disorder (ASD), a 
conditions with multiple aetologies, in children, through the elevated levels of these SCFA 
produced by gut microbiome or from food as propionic acid is a popular food preservative 
[184]. The unscoring mechanism has yet been elucidated.  Epidemiological investigations 
in children exposed to VPA treatment in uterus have reported a significant risk associated 
with ASD and other neurodevelopmental disorders [185]. Indeed, VPA could induce ASD-
like behaviour in rodents when exposed in uterus [186, 187]. Thus, careful consideration 
must be taken to decide whether or not SCFA would be suitable as therapeutics, especially 
in pregnant women or women who are planning to conceive. 
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6. GASTROINTESTINAL DISORDERS 
 
6.1 ULCERATIVE COLITIS 
 
Ulcerative colitis (UC) was first described in the mid-1800s, whereas Crohn’s disease 
(CD) was first reported later, in 1932, as “regional ileitis.” Because Crohn’s disease can 
involve the colon and shares clinical manifestations with ulcerative colitis, these entities 
have often been conflated and diagnosed as inflammatory bowel disease (IBD), although 
they are clearly distinct pathophysiological entities. Ulcerative colitis is the most common 
form of inflammatory bowel disease worldwide. In contrast to Crohn’s disease, ulcerative 
colitis is a disease of the mucosa that is less prone to complications and can be cured by 
means of colectomy, and in many patients, its course is mild [188]. The literature on the 
pathogenesis and treatment of so-called IBD has tended to focus on Crohn’s disease [189, 
190], and few articles expressly discuss ulcerative colitis [191]. Ulcerative colitis and 
Crohn’s disease are disorders of modern society, and their frequency in developed 
countries has been increasing since the mid-20th century. When IBD is identified in a new 
population, ulcerative colitis invariably precedes Crohn’s disease and has a higher 
incidence. Among children, however, ulcerative colitis is less prevalent than Crohn’s 
disease [192]. The highest incidence and prevalence of IBD are seen in the populations of 
Northern Europe and North America and the lowest in continental Asia, where ulcerative 
colitis is by far the most common form of inflammatory bowel disease [193]. A 
westernized environment and lifestyle is linked to the appearance of IBD, which is 
associated with smoking, diets high in fat and sugar, medication use, stress, and high socio-
economic status [194]. IBD has also been associated with appendectomy [194]. Of these 
factors, only cigarette smoking and appendectomy are reproducibly linked to ulcerative 
colitis. 
Bloody diarrhea with or without mucus is the hallmark of ulcerative colitis. The 
onset is typically gradual, often followed by periods of spontaneous remission and 
subsequent relapses. Active disease is manifested as mucosal inflammation commencing in 
the rectum (proctitis) and in some cases spreading to the rest of the colon (figure 6.1.1A). 
Although proctitis is frequently associated with faecal urgency and the passage of fresh 
blood, constipation may paradoxically occur.  
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Proctosigmoiditis, left-sided colitis, extensive colitis, or pancolitis (figure 6.1.1B) 
may lead to diarrhea, frequent evacuations of blood and mucus, urgency or tenesmus, 
abdominal pain, fever, malaise, and weight loss, depending on the extent and severity of 
the disease. The prognosis for patients with ulcerative colitis is generally good during the 
first decade after diagnosis, with a low rate of colectomy; over time, remission occurs in 
most patients [188]. Assessment of the clinical activity of ulcerative colitis helps the 
clinician choose, diagnostic tests and make therapeutic decisions. 
A                                                                           B 
              
Figure 6.1.1. Gross morphological appearance of typical UC specimens. A. Severe inflammation of the rectum, sigmoid, splenic 
flexure and part of the transverse colon, where it stops abruptly and transitions to normal mucosa; B. Severe pancolitis; Pictures taken 
from: Danese, Fiocchi Ulcerative colitis. N Engl J Med. 2011 Nov 3;365(18):1713-25. Doi 10.1056/NEJMra1102942.Review. 
 
In ulcerative colitis, inflammation is characteristically restricted to the mucosal layer, 
with infiltrates varying in density and composition during active disease or stages of 
remission. Infiltrates consist primarily of lymphocytes, plasma cells, and granulocytes; the 
last are being particularly prominent during acute flare-ups and accumulate in crypt 
abscesses [195]. Other typical features include goblet- cell depletion, distorted crypt 
architecture, diminished crypt density, and ulcerations. However, epithelioid granulomas, 
which are typical of Crohn’s disease, are not present. There are no exact criteria for the 
diagnosis of ulcerative colitis, but in most cases, the presence of two or three of the 
aforementioned histological features will suffice [196]. The severity of inflammation on 
histological examination and the severity of disease on endoscopic examination may not 
coincide; for instance, histological findings (figure 6.1.2) may indicate severe disease even 
in a patient with endoscopically quiescent disease. 
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A                                              B                                             C 
     
Figure 6.1.2. Histologic appearance of typical UC mucosal tissue. A. Chronic active colitis with dense and diffuse inflammatory 
infiltrates; B. Chronic quiescent colitis with crypt distortion; C. Neutrophil accumulation in a crypt (crypt abscess) in severe colitis with 
massive leukocyte infiltration of the lamina propria. Pictures taken from: Danese, Fiocchi Ulcerative colitis. N Engl J Med. 2011 Nov 
3;365(18):1713-25. Doi 10.1056/NEJMra1102942.Review. 
 
The gut immune system is generally tolerant of this microbial load, and a breakdown 
in tolerance is postulated to be central to the pathogenesis of IBD [197]. Although loss of 
tolerance to gut microbiota is demonstrable in animal models of IBD, there are none 
evidence for this finding in patients with ulcerative colitis. It has also been postulated that 
alterations in the composition of the gut microbiota, defects in mucosal immunity, or the 
two factors combined could lead to ulcerative colitis; however, supportive evidences are 
sparse. A key issue is the characterization of the gut microbiota in the normal intestine and 
in the intestine in patients with IBD. This issue awaits answers from the Human 
Microbiome Project, which aims to define the composition of the intestinal microbiota in 
conditions of health and disease [198]. There is a consensus that the density of microbiota 
is greater in patients with ulcerative colitis or Crohn’s disease than in healthy control 
subjects, but whether there are reproducible, disease-specific alterations is unclear [199]. 
The fact that antibiotic therapy has no clinical effect on ulcerative colitis argues against an 
important role of bacteria in this disease, whereas antibiotics do provide some benefit in 
luminal Crohn’s disease. Although serum antibacterial antibodies are present in patients 
with ulcerative colitis, they are much more common and are found in higher titers in 
patients with Crohn’s disease. Furthermore, the range of antibodies against bacterial 
antigens is broader in Crohn’s disease, whereas the only ulcerative colitis–associated 
antibody is perinuclear antineutrophil cytoplasmic antibody (pANCA), which recognizes 
nuclear antigens that may cross-react with bacterial antigens [200]. 
Intestinal homeostasis requires a controlled innate immune response to the 
microbiota, which is recognized by toll-like receptors and NOD receptors on epithelial and 
immune cells [201]. This recognition process contributes to tolerance, but when the 
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process is dysregulated, inflammation ensues. At present, there is no clear evidence of 
specific, innate immune defects in ulcerative colitis; an increased expression of TLR2 and 
TLR4 by colonocytes [202] is probably secondary to inflammation. In contrast, in Crohn’s 
disease, abnormalities of innate immunity are linked to variants of the NOD2, ATG16L1, 
and IRGM genes, the products of which normally mediate microbial recognition [203, 
204]. The production of proinflammatory cytokines, such as IL-1β, IL-6, TNF-α, and 
tumor necrosis factor–like ligand 1 (TL1A), is universally increased in patients with IBD. 
Abnormalities in humoral and cellular adaptive immunity occur in ulcerative colitis. 
Elevated IgM, IgA, and IgG levels are common in inflammatory bowel disease, but there is 
a disproportionate increase in IgG1 antibodies in ulcerative colitis [205]. Abnormalities of 
adaptive immunity that differentiate ulcerative colitis from Crohn’s disease are defined by 
mucosal CD4+ T cells, which were initially divided into two lineages: Th1 and type 2 
helper T cells (Th2). UC represents an atypical Th2 response, as indicated by the presence 
of non classical natural killer T cells in the colon that secrete abundant IL-13, which 
mediates epithelial cell cytotoxicity, apoptosis, and epithelial barrier dysfunction [206]. IL-
5–producing Th2-polarized T cells are also present in ulcerative colitis. However, 
additional helper-cell lineages have recently been delineated, including Th17 cells that 
produce the pro-inflammatory cytokine IL-17, the levels of which are increased in the 
mucosa of patients with IBD [207]. 
Because inflammation in ulcerative colitis typically does not extend into the small 
intestine and occurs in proximity to the epithelium, colonocytes are implicated in the 
pathogenesis of this disease. It has been proposed that the epithelium is diffusely abnormal, 
irrespective of inflammation [208]. Other reported abnormalities in ulcerative colitis 
include an epithelial-barrier defect and impaired expression of PPAR-γ, a nuclear receptor 
that regulates inflammatory genes [209]. In both ulcerative colitis and Crohn’s disease, 
epithelial cells have a decreased ability to activate suppressor CD8+ T cells, but this 
abnormality is probably secondary to other immune events [210]. Variants of the XPB1 
gene, the product of which is a component of the stress response of the endoplasmic 
reticulum in epithelial cells, have been linked to IBD, reinforcing the idea that colonocytes 
are involved in its pathogenesis [211].  
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Butyrate and ulcerative colitis 
Host-microbial homeostasis requires appropriate immune regulation within the gut 
mucosa, preventing uncontrolled immune responses against the beneficial commensal 
microbiota, which could potentially lead to inflammatory bowel diseases (IBDs), such as 
UC [212]. Butyrate, the main SCFA, is an organic acid produced by intestinal microbial 
fermentation of undigested dietary carbohydrates, specifically resistant starches and dietary 
fibers, but also in a minor part by endogenous proteins. It is absorbed by the colonic cell 
and extensively metabolized, constituting the main source of energy [58]. The rate and 
amount of SCFAs production depends on the species and levels of microbiota present in 
the colon, the substrate source and gut transit time [58]. 
At intestinal level butyrate exhibits several effects, for example, on transepithelial 
ion transport, on cell growth and differentiation, on inflammatory and oxidative status, on 
non-specific intestinal defense mechanisms and finally on visceral perception and intestinal 
motility [58].  
The importance of butyrate supplementation has been demonstrated by the impaired 
butyrate metabolism in intestinal inflamed mucosa of patients affected by IBD [213]. In 
fact, recent data show that butyrate deficiency results from the reduction of butyrate uptake 
by the inflamed mucosa due to down regulation of the monocarboxylate transporter 
(MCT)-1 expressed on the apical membrane of intestinal epithelium [214]. Particularly, the 
reduction of the intracellular availability of butyrate in colonic cells may decrease its 
protective effects toward cancer in IBD patients [214]. 
The concomitant induction of the glucose transporter GLUT1 suggests that 
inflammation could induce a metabolic switch from butyrate to glucose oxidation. Butyrate 
transport deficiency is expected to have clinical consequences. Particularly, the reduction 
of the intracellular availability of butyrate in colonocytes may decrease its protective 
effects against cancer in IBD patients [105]. In spite of these several preclinical and 
clinical studies analyzing the efficacy of SCFAs mixture or butyrate alone in various 
models of UC, often the results are contradictory.  
To date, several studies have evaluated butyrate effectiveness in several animal model of 
UC [215, 216]. In humans few studies have been performed probably due to low 
compliance with the oral route (for its rancid taste) or rectal enemas administration (for its 
cumbersome application to the patient and irritability due to acid property). Moreover, 
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rectal administration of butyrate or mixture of SCFAs did not show beneficial effects or 
displayed only trends towards clinical amelioration [103, 217]. The discrepancy in human 
studies using enemas may be due to differences in treatment, duration, use of butyrate 
alone or mixture of SCFAs enemas, and use of several concentrations and volumes of these 
mixtures. Conversely, other studies reported that fermentable dietary fiber 
supplementation, which resulted in increased fecal butyrate levels, was effective in 
maintaining remission in UC, revealing a significant improvement in clinical and 
inflammatory aspects [218]. 
Some butyrate-based products are marketed even if their spread is still very limited and 
greatly understaffed in view of the wide spectrum of possible indications, especially in 
chronic diseases where it is possible to predict their lasting use. The unpleasant taste and 
odor make extremely difficult the oral administration of butyrate reducing the compliance.  
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6.2 COW’S MILK ALLERGY 
 
Food Allergy 
Food allergy affects more than 1% to 2% but less than 10% of the population’’ and 
that it remains unclear whether the prevalence is increasing, as confirmed by a 
comprehensive review of the literature.11 In particular, the Centers for Disease Control 
reported that the prevalence of food allergy increased from 3.4% to 5.1% between 1997 
and 2011 in the United States [219]. 
Cow’s milk (2.2%), peanut (1.8%), and tree nuts (1.7%) were the most common 
allergens in children, and shellfish (1.9%), fruits (1.6%), and vegetables (1.3%) were the 
most common allergens in adults. Taking a different perspective using food allergen–
specific serum IgE (sIgE) results obtained in the National Health and Nutrition 
Examination Survey (NHANES) in the United States (2005-2006), Liu et al. [220] 
estimated clinical allergy to cow’s milk, egg, and peanut at 1.8% each in children age 1 to 
5 years. The 2 most recent NHANES performed from 2007-2010 with 20,686 US 
participants included queries on self-reported food allergies. Overall, 8.96% reported food 
allergy, with 6.53% among children [221]. 
Cow’s milk allergy (CMA) is the most common food allergy of infancy and early 
childhood with an estimated prevalence of 2-3% worldwide [222]. Berni Canani et al. 
[223, 224] have demonstrated that dietary management with an extensively hydrolyzed 
casein formula (EHCF) containing the probiotic Lactobacillus rhamnosus GG (LGG) 
results in a higher rate of tolerance acquisition in infants with CMA. The mechanistic basis 
for this effect is not known. 
Although pediatric patients with CMA may be allergic to various milk protein, 
casein, ?-lactoglobulin (BLG) and ?-lactalbumin are considered the cow's milk protein 
with the greatest antigenic potential [225].  
Depending on the nature of the immune response, the pathophysiology of CMA 
involves IgE-mediated (immediate reactions) and non-IgE-mediated (delayed reactions, 
mediated by T cells) hypersensitivity reactions (figure 6.2.1). IgE antibodies are produced 
by plasma cells that are derived from lymphocytes B. IgE production is stimulated by a 
particular subpopulation of helper T cells, TH2 lymphocytes: the differentiation of T cells 
in this particular subpopulation is stimulated by the interaction with specific antigens, 
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including the ones on the surface of parasites and helminths and allergens. When T helper 
cells evolve into TH2 cells, they begin to produce cytokines such as IL-4 and IL-5, which 
stimulate isotype switching of B cells into antibody-secreting IgE cells. These cells are 
involved in adaptive or cell-mediated immunity [226]. Interleukin-4 (IL-4), in turn, 
stimulates the mast cells to release histamine and prostaglandins, triggering the 
inflammatory process. Clinical manifestations of CMA include skin reactions (eg, 
urticaria, angioedema, contact dermatitis), respiratory reactions (eg, dyspnea, rhinitis, 
cough, laryngeal edema, and asthma with severe respiratory distress), and gastrointestinal 
reactions (such as diarrhea and vomiting, bloody stools, constipation, severe irritability of 
the colon). IgE-mediated allergic reactions occur within a few minutes up to an hour after 
exposure to allergens (usually within 10-20 minutes) with a risk of anaphylaxis, while non-
IgE-mediated reactions occur within one hour up to several days after ingestion of an 
allergen [227]. 
In general, healthy individuals with mature immune system develop tolerance to the 
food proteins more ingested and commensal bacteria [228]. Patients can show food allergy 
when the specific oral tolerance to the food eaten is compromised or not properly 
developed. 
Alterations in the microbiota have now been implicated in the pathogenesis of food 
allergy [229]. Intestinal microbiota influences the network of the immune system and 
impairs regulatory functions and TH2 skewing. In human studies, germ-free (GF) 
conditions are almost impossible, limiting the types of analysis that can be performed, 
while a role for commensal microbiota in promoting oral tolerance has been clearly 
defined by using gnotobiotic mice, in which reconstitution of GF mice with well-
characterized communities of microbiota or defined bacteria has been performed. 
Il4raF709 mice carrying a gain of function mutation in IL-4 receptor ?-chain, which are 
susceptible to allergic sensitization and anaphylaxis [230, 231], exhibit an altered gut 
microbiota signature from that seen in control mice. GF mice reconstituted with these 
microbiota exhibit allergic sensitization and anaphylaxis. Transfer of antigen-specific Treg 
cells to Il4raF709 mice is capable of both restoring the normal microbiota and suppressing 
the allergic responses [231]. A recent study demonstrated a successful reconstitution of 
mice with human microbiota that resulted in an increase in Treg cell numbers and 
amelioration of allergic diarrhea [232]. 
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Intriguingly, mice co-housed with or progeny of reconstituted mice with human microbiota 
also exhibited increased Treg cell numbers [232]. These findings suggest that susceptibility 
to or protection against food allergy might be a transmissible trait. These murine 
approaches are powerful tools for dissecting the interaction between the microbiota and 
disease pathogenesis, opening potential investigations into a myriad of human microbiota 
that are beneficial or harmful in the treatment and management of allergic conditions. 
 
The implication of butyrate in cow’s milk allergy 
Allergic infants exhibit an accelerated ecological succession to a community 
structure more typical of the adult microbiota with a significantly reduced abundance of 
Lactobacillales and Bifidobacteriales and increased abundance of Clostridiales. This 
increase in Clostridia is maintained in CMA infants after treatment with extensive 
hydrolyzed casein formula (EHCF) associated to Lactobacillus Rhamnosus GG (LGG) or 
rice hydrolyzed formula (RHF). When examined at the genus level, treatment with 
EHCF+LGG, but not with RHF, is associated with a significant enrichment of the butyrate-
producing Clostridia Faecalibacterium and Roseburia. CMA infants treated with 
EHCF+LGG had correspondingly significantly higher levels of butyrate detectable in their 
feces than infants treated with RHF, which correlated with an accelerated acquisition of 
tolerance. Moreover, the murine model showed promising protective effects of induction 
of oral tolerance on food allergies [233]. 
 
Figure 6.2.1. Difference between two types of cow’s milk hypersensitivity. Image taken from Venter, Journal of Family Health 2010.
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7. EXTRA-INTESTINAL DISORDERS 
 
 7.1 OSTEOARTHRITIS AND CHONDROCYTES 
 
Osteoarthritis (OA), the most prevalent form of arthritis, affects up to 15% of the 
adult population and is principally characterized by degradation of the articular cartilage of 
the joint, associated with subchondral bone lesions. Chronic, low-grade inflammation 
contributes to symptoms and disease progression. Networks of diverse innate inflammatory 
danger signals, including chemokines, cytokines and alarmins are activated in OA. Besides 
inflammatory mediators, biomechanical injury and oxidative stress compromise the 
viability of chondrocytes, leading to hypertrophic differentiation and pro-catabolic 
responses with further extracellular matrix (ECM) degradation. Better understanding the 
inflammatory pathophysiology should help identifying different OA subtypes in the 
population and should lead to the development of new therapeutic options. OA is one of 
the most prevalent diseases of the elderly and is a top cause of disability. There are few 
treatment options for OA patients and most of them aim at reducing pain and controlling 
inflammation to improve function. Non-steroidal anti-inflammatory drugs (NSAIDs) and 
corticosteroid injections are largely used since many years but the current treatment 
strategies have no impact on the progressive degeneration of joint tissues [234, 235]. 
Recent studies suggest that disease-modifying treatments are possible.  
Similar to the approach that has been successful for rheumatoid arthritis (RA), biotherapies 
targeting inflammatory mediators such as TNF-?, IL1 or IL6 have been tested. Although 
these strategies led to a majority of disappointing results [236-238], some biotherapies are 
still under evaluation. In a recent study using adalimumab (a humanized monoclonal 
antibody targeting TNF?) induces statistically significant less erosive evolution on the 
radiological image hand of OA patients with clinical joint swelling [239]. The current data 
indeed suggest that co-inhibition of several pro-inflammatory cytokines may be more 
efficient in OA [240]. In this context, mesenchymal stromal/stem cell (MSC)-based 
therapy seems attractive because this innovative therapeutic strategy could provide an 
enlarged anti-inflammatory potential. MSCs are immunosuppressive cells, which can 
decrease inflammation through the release of anti-inflammatory factors (including IL1RA) 
and decrease monocyte activation [241]. 
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The role of inflammation in OA 
Although OA has generally been proposed as a degenerative disease, recent work 
suggested that low-grade inflammatory processes could promote disease symptoms and 
accelerate disease progression [242]. Some of the cartilage matrix catabolic products 
probably activate macrophages and other innate immune cells to release inflammatory 
cytokines, which in turn promote cartilage damage progression by altering chondrocyte 
function [243]. The interplay between the immune system and cartilage is not well 
understood but evidence of regulation of acute-phase response signaling pathway, the 
complement pathway, and the coagulation pathway in the joint fluid of OA patients has 
been reported, suggesting a contribution of inflammation to joint damage [244]. However a 
correlation with the expression level of PGE2 in the synovial fluid has not been 
demonstrated. Synovial membranes from patients with OA demonstrate low grade 
synovitis compared to RA but with high expression of cytokines. OA synovial tissue shows 
an increase in immune cell infiltrates associated with pro-inflammatory cytokine 
expression, including TNF?, IL1β, IL6, IL8 and IL22. Moreover, activation of the innate 
immune system contributes to the persistence of OA synovial low-grade inflammation. 
Damage to cells and cartilage ECM resulting from repeated microtrauma and senescence 
generates damage-associated molecular patterns (DAMPs) that activate the innate immune 
system through the TLR pathway [245]. DAMPs include fragments generated from ECM 
degradation such as proteoglycans, intracellular proteins such as heat-shock proteins or 
DNA. By inducing the release of alarmins (high mobility group box protein 1 S100A8 and 
S100A9) by monocytes, they contribute to the inflammatory cascade. The inflammatory 
process activates the release of enzymes by chondrocytes and monocytes resulting in 
enhanced catabolic process. These enzymes include proteins of A Disintegrin And 
Metalloproteinase with Thrombospondin motifs (ADAMTS) family and matrix 
metalloproteinases (MMP)1, 3, 13, which are directly responsible of ECM remodeling. It 
has also been shown that the joint synovial fluid from OA patients contains a small number 
of MSCs but their role in OA pathogenesis or cartilage regeneration has yet to be 
established [246]. OA is therefore an inflammatory musculoskeletal disease involving both 
innate and adaptive immune response as shown by high levels of pro-inflammatory 
cytokines and downstream target factors. All these factors are showed in figure 7.1.1. 
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Figure 7.1.1. Osteoarthritis and inflammation. Image taken from The role of synovitis in pathophysiology and clinical symptoms of 
osteoarthritis, Sellam & Berenbaum, Nature Reviews Rheumatology 2010, 06, 625-635, doi:10.1038/nrrheum.2010.159. 
 
Inflammatory biomarkers in osteoarthritis 
Inflammatory OA is a debilitating and highly prevalent disease, but is often sub-
clinical. There is an increasing body of evidence that inflammatory and destructive 
responses of the synovium play a major role in OA [247]. Moreover, the role of 
inflammation in the illness of OA has been recognized through the association of joint 
effusion with joint pain [248]. It is still unclear to what extent inflammation is an initiator 
vs an outcome of the joint destructive process [249]. Of particular interest is the emerging 
evidence that the degree to which the immune and wound healing responses can be 
activated in part controls the predisposition of an individual to chronic diseases, among 
them OA. Despite the global burden of OA, diagnostic tests and treatments for the 
molecular or early subclinical stages are still not available for clinical use. It would of great 
value to be able to readily identify subclinical and/or sub-acute inflammation, particularly 
in such a way as to be appropriate for a clinical setting. Daghestani et al. [250] reviewed 
some important types of biomarkers associated with OA in human studies that point to a 
role of inflammation in OA. 
Among these, cytokines are small proteins released from a wide array of cells, 
including immune cells (macrophages, B lymphocytes, T lymphocytes, mast cells, natural 
killer cells, epithelial cells, endothelial cells, dendritic cells, fibroblasts, and stromal cells) 
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[251]. Various cells utilize cytokines, chemokines (chemotactic cytokines), and adipokines 
(cytokines released by adipose tissue) as part of the inflammatory response to regulate cell 
signaling and interactions within the cell itself and between other cells [252, 253]. 
Cytokines can have either pro-inflammatory or anti-inflammatory properties and often 
work concordantly to maintain cell homeostasis [254]. It has been shown that the 
concentrations of key SF cytokines (IL-1a, IL-18 and TNF-?) were associated with the 
level of OA severity; baseline IL-18 also predicted OA progression [255]. Serum levels of 
IL-6 and TNF-? have also been associated with the prevalence of joint space narrowing 
and prediction of knee cartilage loss [256]. Serum TNF-? levels have effectively been used 
to monitor the efficacy of various OA treatments in rabbits [257]. However, in a multi-
center, randomized, double blind, placebo-controlled trial, injection of anti-TNF-a agents 
did not show any improvement in patients with unmanageable hand OA [237]. Soluble 
TNF-a receptor levels were decreased in the synovial fluid and plasma of patients with OA 
in comparison with healthy controls, with synovial fluid levels being negatively correlated 
with joint symptoms [258] evaluated by the Western Ontario and McMaster University 
Osteoarthritis Index (WOMAC) questionnaire. In a small pilot study, Vangsness et al. 
[259] showed that higher levels of SF IL-2, IL-5, and monocyte chemoattractant protein 
(MCP)-1 were associated with greater degrees of OA severity. Synovial fluid levels of IL-
6, IL-13, and macrophage inflammatory protein (MIP)-1? were elevated in patients with 
endstage knee OA while granulocyte colony-stimulating factor (G-CSF) levels were lower 
when compared to SF levels of healthy controls [260].  
Chemokines are a class of small protein cytokines that act as chemoattractants to 
guide cells to migrate to a specific location, and in the context of inflammation, toward the 
site of injury or pathogenic invasion [251]. Interferon gamma inducible protein 10, also 
known as CXCL-10, is a chemokine that has been shown to be inversely associated with 
radiographic knee OA in both plasma and sinovial fluid. Serum fractalkine, or CX3CL1, 
has been shown to be significantly elevated in patients with knee OA in comparison to the 
sera from healthy individuals [261]. Synovial CXCL12, but not serum CXCL12, was 
associated with radiographic severity of OA [262]. A recent study has demonstrated the 
feasibility of using serum and synovial MCP-1, also known as chemokine ligand 2 
(CCL2), as a biomarker for self-reported pain and physical disability in patients with knee 
OA [263]. To further support the role of macrophages in OA related inflammation, MCP-1 
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has been shown to increase the recruitment of macrophages into adipose tissue [264] and 
atherosclerotic lesions [265].  
A number of adipose tissue-secreted hormones mediate inflammatory effects [266] 
and cartilage catabolism in OA [267, 268]. Plasma adipokines adiponectin, which is 
responsible for modulating metabolic processes, and leptin, a regulator of fat storage, have 
been shown to be positively associated with joint symptom burden, while the glucose 
modulating adipokine, adipsin, was lower in patients with hip and knee OA [269]. Adipsin 
is also known as complement factor D and it is responsible for activating the alternative 
pathway of the complement system [270]. Serum adiponectin levels have also been 
associated with radiographic hand OA progression after 6-year follow-up [271]. Leptin is 
believed to play an important role in the pathogenesis of OA via its stimulation of anabolic 
functions of chondrocytes in cartilage [272]. Serum leptin levels were also associated with 
prevalent and incident knee OA in the Study of Women's Health Across the Nation 
(SWAN) cohort [273]. 
Serum leptin measured at baseline has been associated with increased levels of bone 
formation biomarkers (osteocalcin and procollagen type I N-terminal propeptide (PINP)) 
after 2-year follow-up [274]. In addition, baseline soluble leptin receptor was associated 
with lower levels of procollagen type II N-terminal propeptide (PIIANP) and decreased 
cartilage volume [274]. Visfatin (also known as nicotinamide phosphoribosyltransferase 
(Nampt), which is an adipokine and enzyme involved in the metabolism of nicotinate and 
nicotinamide, has recently been suggested to be a therapeutic target for OA given its role in 
chondrocyte and osteoblast activation [275]. As an inflammatory biomarker, levels of 
synovial visfatin were significantly greater in patients with knee OA compared to control 
subjects [276]. In addition, synovial visfatin was positively correlated with the cartilage 
degradation markers collagen II and aggrecan 1 and 2 and was significantly elevated in 
more severe knee OA grades (Kellgren Lawrence 4 vs 3) [276]. In middle-aged women, 
lower levels of serum estradiol, which is a hormone that has anti-inflammatory properties 
[277], and the urinary estrogen metabolite 2-hydroxyestrone were associated with both the 
prevalence and incidence of knee OA [278]. 
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The role of chondrocyte in osteoarthritis 
OA is a progressive degenerative disease characterized by gradual loss of articular 
cartilage. Since the OA lesion is often localized to weight-bearing cartilage or to sites of 
trauma, repetitive mechanical injury has been proposed as the critical signal for the 
initiation and progression of OA. It is now generally accepted that the chondrocyte is the 
target of these abnormal biomechanical factors, and that biochemical and genetic factors 
also contribute to alterations in the normal functional activities of these cells.  
Even in the absence of classic inflammation, which is characterized by infiltration of 
neutrophils and macrophages into joint tissues, elevated levels of inflammatory cytokines 
have been measured in OA synovial fluid. Although the OA cartilage lesion is present at 
sites remote from the synovium, the fibroblast- and macrophage-like synovial cells, as well 
as the chondrocyte itself, are potential sources of cytokines that could induce chondrocytes 
to synthesize and secrete cartilage degrading proteases, cytokines, and other inflammatory 
mediators  [279]. These synovium- and chondrocyte-derived products represent potential 
targets for the development of therapeutic agents, such as proteinase inhibitors, cytokine 
antagonists, and cytokine receptor blocking antibodies, which could be used to prevent or 
retard the progression of the OA articular lesion. 
Biochemical and genetic factors, as well as mechanical stress, contribute to the OA 
lesion in cartilage by disrupting chondrocyte–matrix associations and altering metabolic 
responses in the chondrocyte [280]. In early OA, the chondrocyte exhibits a transient 
proliferative response (clonal growth), increased synthesis of cartilage matrix as an early 
attempt at repair, and increased synthesis of catabolic cytokines and matrix degrading 
enzymes. Catabolic cytokines may also be generated by the fibroblast- and macrophage-
like cells in the synovium in response to breakdown products from the damaged cartilage. 
Local loss of proteoglycans and cleavage of type II collagen occur initially at the cartilage 
surface, resulting in an increase in water content and loss of tensile strength in the cartilage 
matrix. 
The involvement of chondrocyte-derived MMPs in the degradation of cartilage 
collagens and proteoglycans in OA is well established. The development of antibodies that 
detect specific cleavage epitopes has permitted the analysis of degradation products of type 
II collagen and aggrecan in synovial fluid and cartilage of OA patients [281-283]. MMPs 
have been localized in regions of cartilage degradation [284], and they are elevated in 
synovial fluid and cartilage from OA patients [282, 285]. The levels of the tissue inhibitor 
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of metalloproteinases 1 (TIMP-1) are also increased in OA synovial fluid and correlate 
with the MMP levels [282, 285], possibly reflecting an endogenous adaptive response to 
the increased levels of active proteinase activities. However, the progressive degradation of 
the cartilage matrix that occurs in OA indicates that there is a local imbalance in the 
proteinase/inhibitor content [286]. 
 
Relationship among inflammation, obesity, the gut microbiota, and 
metabolic osteoarthritis 
Emerging evidence suggests that intrinsic inflammatory mediators secreted by body 
fat, or adipose tissue, including cytokines, adipokines, and advanced glycation end 
products, may be sufficient to lead to onset and progression of OA [287]. It appears that 
these obesity-associated, intrinsic inflammatory factors define a metabolic subtype of OA 
[288, 289]. Characterizing the factors that comprise this unhealthy metabolic phenotype is 
critical to understanding the influence of obesity on OA. Furthermore, establishing the 
“indirect” role of the microbiota and the gut is required to fully understand the initiators 
and drivers of metabolic OA. 
Experimental high fat diets (45-60% of energy derived from lard-based fat rich in saturated 
fatty acids) have been associated with an increase in OA independent of gains in body 
weight [290, 291]. However, these diets do not accurately represent the typical human 
Western-type diet, as the high percentage of fat (>50% kcal from fat) would be considered 
extreme. Rather, the obesity epidemic in North America appears driven by processed foods 
high in fat and simple carbohydrates, which is better modeled by a high fat/high sucrose 
(HFS) diet [292]. 
When fed a HFS diet, Sprague Dawley rats, as well as Wistar rats and C57BL/6C mice, 
exhibit obesity prone (top ~50% of weight gainers) and obesity resistant (bottom ~50% of 
weight gainers) phenotypes, where obesity resistant animals grow normally and the prone 
become obese [293]. This feature allows for experimental evaluation where in animals are 
all exposed to the same obesogenic diet but develop disparate body weight [293]. 
Moreover, the effect of HFS diet-induced obesity on OA in prone and resistant animals 
was experimentally evaluated [294]. Although the extent to which inflammatory mediators 
contribute to metabolic OA remains unknown, several cytokines and adipokines detected 
in serum and synovial fluid of obese animals have been implicated [291, 295, 296]. In 
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particular, leptin is elevated in serum and synovial fluid of obese individuals and animals 
with OA [272]. However, the detailed molecular origins of such low-grade systemic 
inflammation remain unknown [297]. Systemically, visceral adipocytes, macrophages, and 
adipose tissue mast cells have been suggested to contribute to this chronic inflammatory 
state [298]. In knee joints, the infrapatellar fat pad and synovial fluid are thought to 
contribute to the local inflammatory environment [268, 299]. Recently, a link between 
low-grade inflammation and changes in the composition and activity of the microbes that 
reside in the gastrointestinal tract, collectively termed the gut microbiota, has been 
established. Notably, high fat diets enhance translocation of the bacterial membrane 
component lipopolysaccharide into the bloodstream, initiating obesity and insulin 
resistance [300]. New evidence suggests that the gut microbiota, through activating innate 
immune responses that lead to systemic inflammation, represent a possible mechanistic 
link to metabolically induced OA [301]. 
 
Butyrate, as histone deacetylase inhibitor and its role in OA 
Acetylation and deacetylation of nucleosomal histones play an important role in the 
regulation of gene expression [302]. The histone acetylation status is controlled by the 
opposing actions of two classes of enzymes: histone acetyl transferases (HATs) and 
histone deacetylases (HDACs). Acetylation of histones loosens nucleosomal structures, 
thereby promoting gene transcription. In contrast, deacetylation of histones stabilizes 
nucleosomal structures and represses gene transcription [302]. However, emerging 
evidence indicates that gene regulation by acetylation/ deacetylation is more dynamic and 
complex, and that HATs can act as repressors and HDAC as activators of transcription. 
Indeed, global analysis of gene expression has shown that inhibition of HDAC activity 
results both in induction and repression of gene expression [303, 304]. 
In recent years, significant interest has emerged in the inhibition of HDAC activity as a 
possible anti-cancer treatment. HDAC inhibitors induce growth arrest, differentiation and 
apoptosis of cancer cells in vitro and reduce the growth of experimental tumors in vivo 
[305]. Presently, several HDAC inhibitors are in clinical trials for the treatment of solid 
and hematological tumors [306, 307]. In addition to their anti-cancer effects, recent studies 
have demonstrated that HDAC inhibitors modulate inflammatory responses. For instance, 
HDAC inhibitors reduce the production of IL-1, tumor necrosis factor-? (TNF-?), and 
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interferon-? (IFN-?) in lipopolysaccharide (LPS)-stimulated human peripheral blood 
mononuclear cells [308, 309]. Likewise, HDAC inhibitors prevent LPS-induced production 
of TNF-?, IL-6 and reactive oxygen species in neuroglia cultures, and primary microglia 
[124, 310, 311]. HDAC inhibitors have also been reported to suppress IL-12 production in 
dendritic cells and macrophages [312]. Moreover, it has been partially demonstrated 
whether HDAC inhibitors regulate inflammatory responses in articular chondrocytes [313]. 
 
7.2 WOUND HEALING 
 
Skin ulcers are one of the most common diseases in the worldwide healthcare 
sector. The ulcer is clinically well defined as chronic wound, one of the most common 
ailments, which seriously affects the life quality of the patient and creates a huge financial 
burden for the health system. Ulcers are caused by chronic injury from a variety of events 
such as trauma, exposure to heat, cold, corrosive material, or radiation, and blood 
circulation problems. It is estimated that in the socially evolved countries the appearance of 
chronic skin ulcers interests a minimum of 1.5% up to a maximum of 3% of the 
population, with an index of hospitalizations of 0.4%, and of the days hospitalization of 
approximately 1% [314]. In Italy it is estimated that ulcers affect approximately two 
million of people, thus assuming the contours of a social disease. Skin ulcers are 
characterized by loss of skin, superficial and deep dermis and subcutaneous tissue, they 
tend to recur and difficultly to heal spontaneously. The ulcers represent a significant risk 
factor for hospitalization, amputation, sepsis and mortality. From the point of view of the 
patient the therapy of the lesions is often painful and uncomfortable [315]. 
It is well known that the wound healing involves a series of processes that require the 
interaction of cytokines and growth factors, produced by different highly specialized cells. 
Many factors can prevent the healing of an ulcer and determine the development of an 
ulcer lesion with associated and high morbidity. Among these may be poor nutrition, 
metabolic disorders such as diabetes. During normal wound healing, it is possible to 
identify four overlapping phases: inflammation, granulation tissue formation, 
epithelialization and remodeling. When these phases are delayed for more than a couple of 
weeks, there is a slow healing, as happens for example in diabetic foot ulcers [316] or, 
more generally necrotic ulcer [317].  
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Inflammation in Wound Repair 
Wound healing is a highly dynamic process and involves complex interactions of 
extracellular matrix molecules, soluble mediators, various resident cells, and infiltrating 
leukocyte subtypes. The immediate goal in repair is to achieve tissue integrity and 
homeostasis [318]. To achieve this goal, the healing process involves three phases that 
overlap in time and space: inflammation, tissue formation, and tissue remodeling (figure 
7.2.1) [319]. During the inflammatory phase, platelet aggregation is followed by 
infiltration of leukocytes into the wound site. In tissue formation, epithelialization and 
newly formed granulation tissue, consisting of endothelial cells, macrophages and 
fibroblasts, begin to cover and fill the wound area to restore tissue integrity. Synthesis, 
remodeling, and deposition of structural extracellular matrix molecules, are indispensable 
for initiating repair and progression into the healing state. 
Cellular responses to injury involve direct cell–cell and cell–matrix interactions, as well as 
the indirect crosstalk between different cell populations by soluble mediators. Indeed, 
complex interactions between the epidermal and dermal compartment are essential. 
During the past decade numerous factors have been identified that are engaged in a 
complex reciprocal dialogue between epidermal and dermal cells to facilitate wound repair 
[320]. The sensitive balance between stimulating and inhibitory mediators during diverse 
stages of repair is crucial to achieving tissue homeostasis following injury. The 
inflammatory response is regarded as the first of a number of overlapping processes that 
constitute wound healing. In skin repair, the infiltrating leukocytes are the principal 
cellular components of the inflammatory response. They are not only effector cells 
combating invading pathogens but are also involved in tissue degradation and tissue 
formation. As such, an excessive or reduced influx or activation of infiltrating leukocytes 
into the damaged tissue may have profound effects on downstream cell migration, 
proliferation, differentiation, and ultimately the quality of the healing response. Continuing 
progress in understanding the essential and complex role of the inflammatory response in 
wound repair will provide strategies to modulate diseases with pathologic tissue 
remodeling, such as healing disorders, various chronic inflammatory disease states, and 
cancer. Tissue injury causes the immediate onset of acute inflammation. It has long been 
considered that the inflammatory response is instrumental to supplying growth factor and 
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cytokine signals that orchestrate the cell and tissue movements necessary for repair [321], 
as shown in figure 7.2.2. In various experimental animal models and human skin wounds, 
it has been demonstrated that the inflammatory response during normal healing is 
characterized by spatially and temporally changing patterns of various leukocyte subsets 
[318, 322]. The well-defined chronology of these events is essential for optimal repair. 
 
Figure 7.2.1. Mediators and mechanisms of inflammation and inflammatory resolution in repair. Tissue injury causes the 
immediate onset of acute inflammation mediated by chemoattractants derived from plasma proteins, resident and recruited hematopoetic 
cells, extracellular matrix and bacteria. Progression to complete wound healing is accompanied by resolution of the inflammatory 
response, which is essential for successful repair. Resolution of inflammation is directed by downregulation of  proinflammatory 
mediators and the reconstitution of normal microvascular permeability, which contributes to the cessation of local chemoattractants, 
synthesis of anti-inflammatory mediators, apoptosis, and lymphatic drainage. An excessive or prolonged inflammatory response results 
in increased tissue injury and poor healing. Successful wound repair requires the coordinate expression of both inflammation and 
resolution of inflammation. (Image taken from Journal Of Investigative Dermatology, Eming et al., 2007) 
 
Successful repair after tissue injury requires resolution of the inflammatory response. 
However, whereas the knowledge about mechanisms and molecules inducing and 
perpetuating the inflammatory response is constantly increasing, mechanisms, that limit 
and down regulate this activity are less appreciated. Such mechanisms might include: 
downregulation of chemokine expression by anti-inflammatory cytokines such as IL-10 
[323] or TGF-?1 [324], or upregulation of anti-inflammatory molecules like IL-1 receptor 
antagonist or soluble TNF receptor; resolution of the inflammatory response mediated by 
the cell surface receptor for hyaluronan CD44 [325]; apoptosis [326], receptor 
unresponsiveness or downregulation by high concentrations of ligands (figure 7.2.3). 
Interestingly, recent in vitro data suggested that MMPs can downregulate inflammation via 
cleavage of chemokines, which then act as antagonists [327]. 
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Figure 7.2.2. Inflammatory cells, their functions and mediators released in tissue repair. (Image from Journal Of Investigative 
Dermatology, Eming et al., 2007) 
 
Figure 7.2.3. Model of multifactorial molecular and cellular mechanisms deleterious in tissue repair. Chronic wounds fail to 
progress through the normal pattern of wound repair, but instead remain in a state of chronic inflammation predominantly characterized 
by abundant PMN and MF infiltration. Persisting inflammatory cells play a major role in the generation of proinflammatory cytokines 
(IL-1, TNF-a, and IL-6) and a protease rich and pro-oxidant hostile microenvironment. Increased proteolytic activity (neutrophil 
elastase, MMP-8, and gelatinase) leads to degradation of growth factors and structural proteins of the extracellular matrix crucial for 
repair. Increased ROS (H2O2, O2_) can lead to direct damage of cells or extracellular matrix molecules, or contribute to increased 
expression of MMPs (MMP-1, -2, -3, -9, and 13). Bacterial components (extracellular adherence protein (Eap), formyl methionyl 
peptides, N-acetylmuramyl-L-alanyl-D-isoglutamine) may contribute to impaired repair mechanisms of the host by interference with 
cell–matrix interactions or promoting the inflammatory response. (Image taken from Journal Of Investigative Dermatology, Eming et al., 
2007)  
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However, the relevance of these mechanisms for cutaneous tissue repair has to be 
further investigated. In recent studies, Nrf-2, a target of the keratinocyte growth factor-1 
was identified as novel transcription factor regulating the inflammatory response during 
repair. The wound healing response in Nrf-2 knockout mice was characterized by a 
prolonged inflammatory response following wound closure, which was most likely 
mediated by prolonged expression of IL- 1? and TNF-? [328]. 
 
The role of butyrate on Wound Healing 
SCFAs (propionate, butyrate and valerate) derive from the bacterial fermentation of 
oligo-polysaccharides and a small part of proteins, peptides and glycoproteins by the 
normal intestinal saprophytic flora (especially at the level of the colon). A derivative of 
butyrate, butiryl-glycerol, seems to have angiogenic activity [329], and the topical 
application of short chain fatty acids facilitates the healing of intestinal ulcers [330, 331]. 
The mechanisms of action of butyric acid, which contribute to the wound healing, 
may include the ability of butyrate to stimulate the platelet-derived growth factor (PDGF), 
which has an important function in wound healing . It was also demonstrated that butyrate 
is able to block the production or signaling of TNF-α and of the factor TGF? in a variety of 
systems [99, 319, 332]. Butyrate may also down-regulate MMPs, and it can modify the 
gene expression of MMPs [333]. 
The butyrate, besides being a source of energy to epithelial cells, may have potential 
anticancer and anti-inflammatory properties, may also have effects on the intestinal barrier 
and play a role in the sense of satiety and oxidative stress [72]. 
Some factors related to the physic-chemical properties of butyric acid invalidated the 
assumption of this substance. It is also important to remember that butyric acid has a strong 
smell of rancid cheese, it is liquid at room temperature and in time undergoes degradation 
phenomena that alter the stability. 
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8. MATERIAL AND METHODS 
 
8.1 IN VIVO MODELS 
 
8.1.1 DEXTRAN SODIUM SULPHATE-INDUCED COLITIS IN 
MICE 
 
DSS-induced colitis and animal treatments 
Experimental colitis was induced in ten weeks old BALB/c male mice (25±2 g) 
(Harlan-Corezzano, Italy) by 2.5% DSS (wt/vol) (MP Biomedicals, Irvine, CA) in sterile 
drinking water ad libitum for five days, followed by drinking water without DSS for 
twelve days. Mice were randomly divided into six groups (n=10 each group) as following: 
1. a control animals (CON), 2. DSS treated mice (DSS), 3. DSS mice treated with sodium 
butyrate as preventive therapy (PREV Butyrate), 4. DSS mice treated with N-(1-
carbamoyl-2-phenylethyl) butyramide (FBA) as preventive therapy (PREV FBA) 5. DSS 
mice treated with sodium butyrate as curative therapy (CUR Butyrate). 6. DSS mice 
treated with FBA as curative therapy (CUR FBA). We have recently obtained a high 
palatable synthetic butyrate derivative, N-(1-carbamoyl-2-phenylethyl) butyramide (FBA; 
Italian patent RM2008A000214; April 21, 2008). FBA is present in a solid, poorly 
hygroscopic, easily weighable form, stable to acids and alkalis and capable of releasing 
butyric acid at small and large bowel level in a constant manner over time. This product 
has demonstrated a toxicological profile comparable to that of butyrate; it shows 
physicochemical characteristics distinctly more suitable for extensive clinical use than 
those of butyrate. A particular aspect of FBA is that it does not present the unpleasant 
odour of butyrate and is practically tasteless, thus making possible to overcome the main 
limitation to the use of butyrate in the therapeutic field, namely its very poor palatability. 
Moreover, the solubility of FBA in water is satisfactory in that it produces clear solutions 
up to the concentration of 0.1 M and suspensions for higher concentrations. The oral 
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treatment with Butyrate (20 mg/kg/die) or FBA (42.5 mg/kg/die), started 7 days before 
DSS challenge (PREV) or two days after (CUR) DSS challenge and continued for all 
experimental period (20 days). DSS group without pharmacological treatments received 
H2O+Tween20 0.01% as both drug’s vehicle. Colitis was assessed by the daily monitoring 
of body weight, stool consistency and fecal blood. All procedures involving animals were 
carried out in accordance with the Institutional Guidelines and complied with the Italian 
D.L. no.116 of January 27, 1992 of Ministero della Salute and associated guidelines of the 
European Communities Council Directive of November 24, 1986 (86/609/ECC). Prior to 
sample collection, animals, kept overnight fasted, were euthanized by an isoflurane 
anesthesia, followed by cervical dislocation to minimize pain. All efforts were made to 
minimize animal suffering. Blood samples from animals were collected by cardiac 
puncture and serum obtained. At 20th days mice were killed and full intestine and colons 
measured. Colon tissue was excised and immediately frozen. Segments of colon were 
assessed histologically by hematoxylin and eosin staining. In figure 8.1.1a the scheme of 
experimental protocol and animal treatments are summarized. 
 
 
Figure 8.1.1a. Experimental protocol used in this study 
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Evaluation of experimental colitis 
In all animals, weight, presence of blood and stool consistency were determined 
daily as previously described [334]. Disease activity index (DAI) was determined by 
combining scores of a) weight loss b) stool consistency and c) bleeding (divided by 3). 
Each score was determined as follows, change in weight (0:<1%, 1: 1–5%, 2: 5–10%, 
4:>15%), stool blood (0: negative, 2: positive) or gross bleeding (4), and stool consistency 
(0: normal, 2: loose stools, 4: diarrhea) as previously described [335]. Body weight loss 
was calculated as the percent difference between the original body weight and the actual 
body weight on any particular day. Typically in DSS colitis animals will lose 10–15% 
body weight over the course of 10 days. The appearance of diarrhea is defined as 
mucus/fecal material adherent to anal fur. The presence or absence of diarrhea was scored 
as either 1 or 0, respectively, and the cumulative score for diarrhea was calculated by 
adding the score for each day and dividing by the number of days of exposure. Rectal 
bleeding was defined as diarrhea containing visible blood/mucus or gross rectal bleeding 
and scored as described for diarrhea. 
 
Measurement of MPO activity 
Proximal colonic tissues were homogenized twice for 30s at 4°C in 0.5% 
hexadecyltrimethylammonium bromide (HTAB) in 50 mM sodium phosphate, pH 6.0, 
according to Bradley et al., [336]. The homogenates were clarified by centrifugation at 
13000xg for 15 min, at 4°C, and were assessed for MPO activity in 3 ml 50 mM sodium 
phosphate, pH 6.0, containing 16 mM aqueous guaiacol and 5.9 mM H2O2, as previously 
described [337]. The increase in absorbance was measured for 2 min at 470 nm using The 
iMark microplate absorbance reader (Bio-Rad). Protein concentrations were determined 
using the Bio-Rad protein assay. MPO activities were expressed in U.MPO/mg protein 
with 1 U hydrolyzing 1 μmol H2O2/min. 
 
Real-time semi-quantitative PCR 
Total RNA isolated from colon was extracted using TRIzol Reagent (Invitrogen 
Biotechnologies), according to the manufacturer’s instructions. cDNA was synthesized 
using a reverse transcription kit (Maxima First Strand cDNA Synthesized Kit, Fermentas, 
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Ontario, Canada) from 2 μg total RNA. PCRs were performed with Bio-Rad CFX96 
Connect Real-time PCR System instrument and software (Bio-Rad Laboratories). The 
primer sequences for GPR43, IL-10, IL-6, TNF-?? Occludin and ZO-1 were purchased by 
Eurofins MWG Operon (Huntsville, AL, USA) and are reported in Table 1. For Annexin 
A1 (AnxA1), Ccl2, CD14, CD68, Fpr1, Fpr2, GAPDH, Ly-6G and NOS2 we used 
QuantiTect® Primer Assays for SYBR Green by Qiagen. The PCR conditions were 15 min 
at 95°C followed by 40 cycles of three-step PCR denaturation at 94°C for 15 s, annealing 
at 55 or 60°C for 30 s and extension at 72°C for 30 s. Each sample contained 40-100 ng 
cDNA in 2X Power SYBRGreen PCR Master Mix (Applied Biosystem) and 200 nmol/l of 
each primer in a final volume of 25 μl. The relative amount of each studied mRNA was 
normalized to GAPDH as housekeeping gene, and the data were analyzed according to the 
2-ΔΔCT method. 
 
Table 1. Real-Time PCR Primer Sequence 
Target 
gene 
 
Forward primer (5’→3’) 
 
Reverse primer (3’→5’) 
 
Accession 
Number 
GPR43 TTCTTACTGGGCTCCCTGCC TACCAGCGGAAGTTGGATGC NM_146187 
 
HDAC9 GCGGTCCAGGTTAAAACAGAA GCCACCTCAAACACTCGCTT NM_001271386.1 
 
IL-10 GGTTGCCAAGCCTTATCGGA ACCTGCTCCACTGCCTTGCT NM_010548.2 
 
IL-6 ACAAGTGGGAGGCTTAATTACACAT  
 
TTGCCATTGCACAACTCTTTTC  
 
NM_031168.1 
 
MCT-1 GAGCGCGCGAAGCTGCATTTGCT TGCTCCCAGGCCCGCTTTACA NM_009196.3  
 
PPAR-? CTGCTCAAGTATGGTGTCCATGA ATGAGGACTCCATCTTTATTCA  NM_001127330.1   
Occludin ATGTCCGGCCGATGCTCTCTC CTTTGGCTGCTCTTGGGTCTGTAT NM_008756.2 
 
TNF-? 
 
CATCTTCTCAAAACTCGAGTGACAA TGGGAGTAGATAAGGTACAGCCC NM_012675.3 
ZO-1 ACCCGAAACTGATGCTGTGGATAGA AAATGGCCGGGCAGAACTTGTGTA NM_001163574.1 
 
Immunofluorescence analysis of GPR43 
Colonic and liver tissue samples for immunofluorescence were embedded in O.C.T. 
(Pelco Cryo-Z-T, Ted Pella inc, Redding, California), and cryosectioned (10 µm thick). 
Tissue sections were then fixed in 4% paraformaldehyde for 10 min at room temperature 
(RT) and washed in TBS with 0.05% TX-100. For immunofluorescence detection of Ly-
6G, sections were blocked with 10% FCS in TBS for 30 minutes at RT and then incubated 
with a monoclonal antibody anti Ly-6G-FITC (BD Biosciences) overnight at 4°C. To 
63 
 
examine co-localization of AnxA1 and GPR43 with Ly-6G, rabbit monoclonal anti-AnxA1 
antibody [338] and goat polyclonal anti-GPR43 antibody (Santa Cruz Biotechnology, Inc.) 
were incubated alongside anti Ly-6G-FITC antibody overnight at 4°C. Sections were 
washed in 1% FCS plus 0.025% TX-100 and incubated with Alexa-Fluor® 546 goat anti-
rabbit IgG (for AnxA1) and with Alexa-Fluor® 594 donkey anti-goat IgG (for GPR43) 1 h 
at RT. After incubation with secondary antibody, sections were washed in TBS, and then 
incubated with DAPI to visualize nuclei. Slides were mounted in mounting medium 
(Vectashield; Vector Laboratories, Burlingame, California, USA). Fluorescence was 
visualized on a Olympus BX51 fluorescence microscope (Olympus) equipped with a DS-
QiMc monochromatic camera (Nikon) and X-Cite® Series 120Q Xenon lamp. NIS-
Elements BR3.1 software (Nikon) was used for all analyses. Merge images were 
performed with ImageJ software. Two negative controls were used: slides incubated with 
or without primary antibody. Images were recorded at identical gain settings, performed in 
duplicate in non-serial distant sections, and analyzed in a double-blind manner by two 
different investigators. Four image fields were taken of each section. 
 
Serum adiponectin detection 
Whole blood taken through cardiac puncture was centrifuged after 24h at 1500xg at 
4°C for 15 min. So serum obtained was stored at -80°C and then used for adiponectin 
levels detection by Enzyme Linked Immuno Sorbent Assay (ELISA) (Quantikine® 
Immunoassay, RD & SISTEMS, Minneapolis, MN) following manufacturer’s instructions. 
 
Statistical analysis 
Data are presented as mean ± SEM. Statistical analysis was performed by ANOVA 
test for multiple comparisons followed by Bonferroni’s test, using Graph-Pad Prism 
(Graph-Pad software Inc., San Diego, CA). Statistical significance was set at P<0.05. 
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8.1.2 FOOD ALLERGY MODEL 
 
Experimental design 
 Female specific pathogen free C3H/HeOuJ mice were purchased from Charles River 
Laboratories Italia (Calco, Lecco, Italy), maintained on cow’s milk protein free standard 
mouse chow and housed in the animal facility at the Department of Pharmacy, University 
of Naples “Federico II”. All experiments were performed in accordance with the 
Institutional Animal Care and Use Committee of the University of Naples “Federico II”. 
Mice were treated by daily gavage with 20 mg/kg/day of sodium butyrate (Sigma-Aldrich, 
Steinheim, Germany) beginning at two weeks prior to sensitization and continuing 
throughout the sensitization protocol. Sensitization to the cow’s milk protein β-
lactoglobulin was performed according to a previously established protocol, with slight 
modifications [226]. Briefly, 5 week old mice received 20 mg of β-lactoglobulin (BLG, 
Sigma-Aldrich) in 0.2 ml of PBS mixed with 10 μg cholera toxin (CT) (Sigma-Aldrich) 
intragastrically on day 0, 7, 14, 21, and 28; control mice received CT in PBS alone. The 
experimental design is described in figure 8.1.2a. 
 
 
Figure 8.1.2a. Experimental protocol of sensitization with BLG and of butyrate treatment 
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Acute skin response and hypersensitivity symptoms 
One week after the last sensitization, the acute allergic skin response was determined at 1 h 
after intra-dermal challenge with 10 μg BLG in the ear pinnae [339]. Ear thickness was 
measured in duplicate using a digital micrometer (Mitutoyo Italiana Srl, Milan, Italy). 
Allergen-specific net ear swelling was calculated by correcting the allergen-induced 
increase in ear thickness with the baseline value obtained before intra-dermal challenge. 
The ear swelling is expressed as delta micrometers. On the day after acute allergic skin 
response evaluation the same mice were challenged intragastrically with 0.2 ml of BLG 
(50 mg). One hour following the oral BLG challenge, hypersensitivity symptoms were 
scored by a person blind to the study, using a scoring system previously described [339]. 
The scores were as follows: 0 = no symptom; 1 = scratching and rubbing around the nose 
and head; 2 = reduced activity; 3 = activity after prodding and puffiness around the eyes 
and mouth; 4 = no activity after prodding, labored respiration, and cyanosis around the 
mouth and the tail; and 5 = death. Within 2h later, blood samples were collected, 
centrifuged for 15 min at 20,000g and stored at -70°C for measurement of BLG specific 
IgE by ELISA assay. 
 
Measurement of BLG-specific IgE 
Serum IgE anti-β-lactoglobulin (BLG) levels were measured by ELISA as 
previously described [340]. Briefly, 96-well plates were coated with 1 μg/ml of BLG in 
0.05 M sodium carbonate-bicarbonate coating buffer. After overnight incubation at 4°C, 
the plates were washed 3 times with 50 mM Tris, 0.14 M NaCl, 0.05% Tween 20 and 
blocked with 50 mM Tris, 0.14 M NaCl, containing 1% bovine serum albumin for 1 hour. 
The plates were washed repeatedly prior to addition of serum samples and incubation for 2 
hours at 37°C. Plates were then washed four times and 100 μl of biotin-labeled rat anti-
mouse IgE antibody (BD, Pharmingen) was added for 1 hour at 37°C. The plates were 
washed again prior to incubation with streptavidin-horseradish peroxidase (Dako, 
Denmark) for 1 h. The plates were developed by the addition of 3, 3’-5, 5’-tetramethyl-
benzidine (TMB) (Sigma) for 30 min at 25°C in the dark, stopped with 1 M H2SO4, and 
read on a micro-plate reader (Bio-RAD Model 680) at 450 nm. Results are expressed as 
optical density (OD). 
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Measurement of gut permeability in vivo 
An additional group of mice was sensitized with BLG plus CT for 5 weeks as 
described above. After oral challenge with 50 mg of BLG the mice were fasted for 6 h and 
then gavaged with 4,000 kDa FITC-labeled dextran diluted in water (TdB Consultancy 
AB, Uppsala, Sweden) (500 mg/kg, 125 mg/ml). After 2 h, blood (500 μl) was collected 
from intracardiac puncture and centrifuged (3,000 rpm for 15 min at RT), and FITC 
dextran concentration in plasma was determined by spectrophotometer (excitation wave 
length 485 nm; emission wave length 535 nm; HTS-7000 Plus-plate-reader; Perkin Elmer, 
Wellesley, Massachusetts, USA), as previously described [95]. 
 
Measurement of IL-4 from spleen lysates 
Spleen lysates were prepared as previously described [341]. Briefly, individual spleens 
were placed in Eppendorf tubes containing 0.5 ml of lysate buffer. The spleen cells were 
lysed and homogenized by sonication for 30 s on ice. Supernatants were collected after 
centrifugation at 17,500 g for 10 min at 4°C and stored at -20°C. Interleukin-4 (IL-4) from 
spleen lysates was analyzed by commercially available ELISA kits following the 
manufacturer's protocol (R&D systems, Space Import-Export srl, Milan, Italy). 
 
Statistical analysis 
Two-group comparisons were made by t test. One-way ANOVA with Bonferroni 
post-test was used for comparisons between three or more groups. Fisher’s exact test was 
used for categorical variables. 
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8.1.3 WOUND HEALING MODELS 
 
Skin Ulceration induced by doxorubicin 
Housing of animals and anesthesia were performed following the guidelines established by 
the Institutional Animal Welfare committee with the European guide for care and use of 
laboratory animals. Standardized skin ulceration was performed by intradermal 
doxorubicin (Doxorubicin Teva 0.2%) injection on the shaved dorsum of male Sprague-
Dawley rats, as previously described in mice [342]. In brief, animals were anesthetized 
intraperitoneally with uretan (5 g/50 ml and 1,2 ml/100 g w/w of animals). The backs of 
the mice were shaved with a hair clipper and depilated with Veet depilatory cream (Reckitt 
Benckiser, Massy, France). Two days after depilation, mice received 500 µl of a 2 mg/ml 
doxorubicin solution by intradermal injection on the depilated area. The maximum of skin 
ulcer area was reached 11 days after doxorubicin injection. That day (day 1) was the first 
day of treatment with sodium butyrate (20 mg/Kg) and its derivative FBA (42.2 mg/Kg). 
Ulcers were photographed every 2 days (days 1, 3, 5, 8, 10, 12, 14, 17, 19, and 21) and 
cleaned until their complete closure. The lesion size was measured three times by using 
ImageJ software (http://imagej. nih.gov/ij/) for each ulcer, and the mean was calculated. 
Biological samples for molecular analysis were taken from sacrificed animals on days 1, 3, 
5, 10, 17, 19, and 30 after the first application of the ointment, whereas biochemical 
analysis was done on days 1, 5, and 10. In figure 8.1.3a the scheme of experimental 
protocol and animal treatments are summarized. 
 
Figure 8.1.3a Experimental protocol of wound healing induced by doxorubicin. 
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Wound healing induced by mechanical damage 
Six week old male C57BL/6J (Charles River, Calco, Italy) mice were anesthetized with 2–
3% isoflurane, shaved, and a full thickness middorsal wound (0.5-cm2 surface,circle 
shaped) was created by excising the skin and the underlying panniculus carnosus with 
bioptic instrument. The wounds were allowed to dry and form a scab. The subcutaneous 
treatment (10 μl/ mouse) with vehicle (80% of sterile saline solution/10% of PEG 400/10% 
0f TWEEN 80), sodium butyrate (1-10 μg) or FBA (1-10 μg) was performed daily just 
after the induction of wound until complete healing. Wound closure was measured after 3, 
7 and 14 days in a double blinded fashion on control and treated mice. To measure the 
wound area for each mouse was taken a picture of wound and analyzed using ImageJ 
software (http://imagej. nih.gov/ij/). In figure 8.1.3b the scheme of experimental protocol 
and animal treatments are summarized. 
 
Figure 8.1.3b Experimental protocol of wound healing induced by excising. 
Statistical analysis 
Data are presented as mean ± SEM. Statistical analysis was performed by ANOVA 
test for multiple comparisons followed by Bonferroni’s test, using Graph-Pad Prism 
(Graph-Pad software Inc., San Diego, CA). Statistical significance was set at P<0.05. 
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8.2 IN VITRO MODEL 
 
8.2.1 INDUCTION OF INFLAMMATION IN MURINE 
CHONDROCYTES 
 
Cell culture 
ATDC5 cells were a kind gift from Dr. Agamemnon E. Grigoriadis (King’s 
College, London Guy’s Hospital, London, UK). Cells were grown in a standard medium of 
Dulbecco’s modified Eagle’s medium (DMEM)/F-12 containing 5% fetal bovine serum 
(FBS), 10 µg/ml human transferring, 3 X 10-8M sodium selenite, and antibiotics (50 
units/ml penicillin and 50 µg/ml streptomycin) at 37_C under 5% CO2. The medium was 
replaced every two days. Fetal bovine serum (FBS), tissue culture media, media 
supplements were purchased from Sigma (St. Louis, MO). 
 
MTT assay 
Cell metabolic activity was examined using a colorimetric assay based on the MTT 
labeling reagent. Cells were seeded in 96-well plates (8,000 cells/well). Assays were 
performed according to the instructions and protocol provided by the manufacturer 
(Sigma–Aldrich). Spectrophotometrical absorbance was measured using a microtiter 
ELISA reader at 550 nm (Multiskan EX, Termo Labsystem, Barcelona, Spain). 
 
Cell treatments and nitrite assay 
ATDC5 cells were seeded at a density of 106 cells/well into 6-well dishes. After 12 
hours of starvation in serum-free DMEM/Ham’s F-12 medium, cells were stimulated for 
24 hours with mouse interleukin (IL)-1 (0.5 ng/ml) (Sigma Aldrich) and pre-treated or not 
for 1 h with 10-50-100-250 µM of sodium butyrate (Sigma Aldrich) under an atmosphere 
of 5% CO2 for 24 h. Twenty-four hours was the time selected for optimal observation 
according to our time-course experiments.  
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Nitrite accumulation was measured in the culture medium by Griess reaction. Briefly, 100 
µl of cell culture medium was mixed with 100 _l of Griess reagent (equal volumes of 1% 
[weight/volume] sulfanilamide in 5% [volume/volume] phosphoric acid and 0.1% [w/v] 
naphtylethylenediamine HCl), incubated at room temperature for 10 minutes, and then the 
absorbance at 550 nm was measured in a microplate reader (Titertek Multiscan; 
Labsystems, Helsinki, Finland). Fresh culture medium was used as blank in all the 
experiments. The amount of nitrite in the samples (in µM) was calculated from a sodium 
nitrite standard curve freshly prepared in culture medium. 
 
RNA isolation and reverse transcriptase–polymerase chain reaction 
(RT-PCR) 
RNA was extracted using a NucleoSpin kit, according to the instructions and 
protocol provided by the manufacturer. For relative quantification, we performed an RT 
reaction with a First Strand Kit from SABiosciences. Next, real-time PCR was performed 
with a SABiosciences Master Mix and specific RT2 qPCR primers for: mouse Nos2 (122 
bp, NM_010927), Ptgs2 (135 bp, NM_011198.3), Interleukin-6 (178 bp, NM_031168.1), 
Vcam-1 (146 bp, NM_011693.3), ICAM-1 (122 bp, NM_000201.2), lipocalin-2 (81 bp, 
NM_008491.1), nesfatin-1 (NUCB2, from SOLARIS, Thermo Scientific), MMP13 (88 bp, 
NM_008607), Col2a1 (138 bp, NM_031163.3), Ccl3 (112 bp, NM_011337.2), Cx3cl1 
(113 bp, NM_009142.3), Annexin-a1 (70 bp, NM_010730.2), Ffar2 (156 bp, 
NM_146187.4). These gene expressions were normalized with mouse Gapdh (140 bp, 
NM_008084.2). Results of comparative real-time PCR were analyzed with MxPro version 
4 software (Stratagene, La Jolla, CA). 
 
Western blot analysis 
To determine iNOS, VCAM-1 and lipocalin-2 protein expression, ATDC5 cells 
were incubated with IL-1 for 24 hours. Moreover, to evaluate p65 translocation and IκB-α 
degradation, cells were pre-treated with sodium butyrate (250 µM) for 12 hours and then 
challenged with IL-1α (0.5 ng/mL) for 15 or 30 min. Afterwards, cells were subjected to a 
differential lysis to obtain the nuclear and cytosolic fractions as previously described [343]. 
In other set of experiments, to assess the phosphorylation of extracellular signal-regulated 
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kinase (ERK1/2), p38, Akt and AMPKα, cells were pre-treated with sodium butyrate (250 
µM) for 12 hours and then challenged with IL-1α (0.5 ng/mL) for 30 min. In both 
experiments, after the stimulation, cells were washed twice with ice cold PBS, harvested, 
and resuspended in lysis buffer for protein extraction (10 mM Tris/HCl, pH 7.5, 5 mM 
EDTA, 150 mM NaCl, 30 mM sodium pyrophosphate, 50 mM sodium fluoride, 1 mM 
sodium orthovanadate, 0.5% Triton X-100, 1mM PMSF, protease inhibitor cocktail). Cell 
lysates were obtained by centrifugation at 14.000xg for 20 min at 4°C. Protein 
concentrations were estimated by the Bio-Rad protein assay using bovine serum albumin 
as standard. Lysates from control or stimulated cells were collected and separated by 
SDS/PAGE on a 10% polyacrylamide gel. Proteins were subsequently transferred to a 
polyvinylidene difluoride transfer membrane (Immobilon-P transfer membrane, Millipore, 
MA) using a transfer semidry blot cell (BioRad Laboratories). Blots were incubated with 
the appropriate antibodies: anti-iNOS and anti-VCAM-1 (Cell Signaling Technology, 
Denver, Massachusetts, USA), lipocalin-2 (R&D Systems, Inc., Minneapolis, MN, USA), 
anti-phospho ERK1/2 and anti-ERK1/2 (Millipore, MA, USA), anti-phospho-p38 and anti-
p38 (Millipore, MA, USA) ), anti-NFκB p65 (Santa Cruz, CA,USA), anti-IκB-α, anti-
phospho-Akt and anti-Akt, anti-phospho-AMPK-α and anti-AMPK-α (Cell Signaling 
Technology, Denver, Massachusetts, USA). Immunoblots have been visualized with 
Immobilon Western Detection kit (Millipore, MA) using horseradish peroxidise labelled 
secondary antibody. To confirm equal loading in each sample, the membranes were 
stripped in stripping buffer (100 mM β-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 
6.7) and re-blotted with anti-GAPDH (Sigma, MO, USA) or anti-lamin-β1 antibody 
(GeneTex, CA, USA). The images were captured and analyzed with an EC3 imaging 
system (UVP). Densitrometric analyses were performed using ImageJ software (National 
Institutes of Health, Bethesda, MD, USA). 
 
siRNA-mediated gene silencing of GPR43 receptor 
In order to silence GPR43 gene, we used the siRNA that targets GPR43 receptor 
(Integrated DNA Technologies, USA) and the siRNA negative control, that does not target 
any known sequence. Transfection with 10nM of siRNA duplex was performed using the 
cationic lipid siLentFect (BioRad, CA, USA) according to the manufacturer’s 
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recommendations. Cells were transfected for 48 h and then they were stimulated with 0.5 
ng/ml of IL1 in presence or not of 250 µM of sodium butyrate for 24 h. 
 
Statistical analysis 
Data are reported as mean ± standard error mean (S.E.M.) values of independent 
experiments, which were done at least three times, each time with three or more 
independent observations. Statistical analysis was performed by analysis of variance test, 
and multiple comparisons were made by Bonferroni’s test or, when appropriate, with 
Dunnet’s test. Statistical significance was set at P<0.05. 
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9. RESULTS 
9.1 N-(1-CARBAMOYL-2-PHENYL-ETHYL) BUTYRAMIDE, A NEW 
SYNTHETIC BUTYRATE DERIVATIVE, REDUCES INTESTINAL 
INFLAMMATION IN DEXTRAN SODIUM SULPHATE-INDUCED 
COLITIS. 
 
Effect of Sodium butyrate and FBA on weight change and disease 
activity index in DSS mice 
As shown in figure 9.1.1 A both pharmacological treatments (preventive and curative 
protocol) were able to preserve weight loss induced by DSS challenge (*P<0.05; **P<0.01 
vs. CON). As reported in AUC graph, curative treatment appeared more effective than 
preventive one. Assessment of disease activity index (DAI) after 7 days from 12th day 
showed a strong increase of colitis gravity in DSS-challenged mice (***P<0.001 vs. CON). 
Instead, butyrate and FBA (PREV and CUR) significantly prevented the development of 
colitis manifestations (figure 9.1.1 B) (### P<0.001 Vs. DSS).  
 
Butyrate and FBA improve tissue histopathology and prevent colon 
shortening in DSS- induced colitis 
Control colon sections  showed the intact epithelium, well defined crypt length, no 
edema, no neutrophil infiltration in mucosa and submucosa, and no ulcers or erosions. In 
contrast, colon tissue from DSS treated mice showed clear and severe inflammatory lesions 
extensively throughout the mucosa (figure 9.1.2 A). Ulcers, shortening and loss of crypts 
were seen focally at the beginning progressing to more extensive areas of mucosal 
involvement and finally the whole colon. Infiltration of immune cells including neutrophils 
and lymphocytes were seen in the lamina propria in DSS mice. In spite of DSS treatment, 
butyrate and FBA were able to protect colonic mucosa structure and to reduce immune 
cellular recruitment. 
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Figure 9.1.1. Effects of Butyrate and FBA on induction and recovery from DSS induced colitis. WT mice received 2.5% DSS for 5 
days followed by treatment and then returned to normal drinking water for an additional 7. Mice were sacrificed on day 12. (A) 
Evolution of body weight and (B) DAI values on day 12. Data are mean ± SD from eight mice/group. 
 
In addition both preventive and curative treatments ameliorated mucosa integrity and 
crypt structure improving epithelial surface. Beneficial effects of all therapeutics schemes 
were shown macroscopically after colon excision. In fact, as depicted in figure 9.1.2 B, 
butyrate and FBA preserved colon from inflammation and bleeding induced by DSS. 
Furthermore, both therapeutic protocols, in particular curative ones, with butyrate and FBA 
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reduced colon shortening shown in DSS-challenged mice (figure 9.1.2 C) (*P<0.05 vs 
CON; #P<0.05 and ##P<0.01 vs. DSS). 
                               A 
 
         B                                                                    C 
     
 
Fig. 9.1.2. Therapy with Butyrate and FBA ameliorates DSS colitis. (A) Representative histology of the distal DSS colon (H&E 
staining; original magnification 200X, bar 0.2 mm). Black arrows indicates infiltrated cells in the submucosa. (B) Colon images and (C) 
assessment of total colon length after DSS treatment. Data are mean ± SD from eight mice/group. Histological images are representative 
of 5 slides for each group. 
77 
 
Anti-inflammatory effect of butyrate and FBA in colon and serum 
Colonic inflammation was determined by TNF-α, IL-6, COX-2 and IFNγ mRNA 
(figure 9.1.3 A-B-C-D). All these cytokines were significantly up-regulated in DSS-
challenged mice, conversely mRNA of anti-inflammatory mediators such as IL-10, 
adiponectin, PPARγ were reduced (figure 9.1.4 A-B-C-D) (*P<0.05; **P<0.01 vs. CON). 
Protective effect of butyrate and FBA (PREV and CUR) was shown not only in reducing 
pro-inflammatory mediators but also in recovering anti-inflammatory factors in colon 
tissue and serum (#P<0.05; ##P<0.01; ###P<0.001 vs. DSS). 
 
    A                                                                      B 
 
    C                                                                     D 
 
Figure 9.1.3. Butyrate and FBA inhibit secretion of pro-inflammatory mediators. mRNA transcriptional levels of (A) TNF-???(B) 
IL-6, (C ) COX-2 and (D) IFNγ in colon tissue. Data are presented as means ± standard error of 5 animals for each group. 
 
Moreover, DSS was able to induce significantly HDAC9 mRNA transcript (figure 
6.1.4 D). Instead, butyrate and FBA, when used as curative treatments, down-regulated 
HDAC9 mRNA levels (#P<0.05; ##P<0.001 vs. DSS). 
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    A                                                                      B 
 
    C                                                                      D 
 
Figure 9.1.4. Butyrate and FBA restore anti-inflammatory factors and inhibit HDAC9. mRNA transcriptional levels of (A) IL-
10??(B) adiponectin, (C ) PPARγ and (D) HDAC9 in colon tissue. Data are presented as means ± standard error of 5 animals for each 
group. 
 
Protective effect of Butyrate and FBA in restoring intestinal barrier 
integrity 
IBDs are characterized  by inappropriate and ongoing activation of the mucosal immune 
system driven by penetration of normal luminal flora due to tight-junction defects of the 
intestinal epithelial barrier. In our experiment, we demonstrate that butyrate and its 
derivative FBA were able to significantly restore the intestinal barrier integrity 
compromised by DSS, inducing the increase of mRNA levels of occluding and zonulin 
(ZO)-1, two of most important tight-junction of the intestinal tract(figure 9.1.5 A-B) 
(*P<0.05 and ***P<0.001 vs CON; #P<0.05 vs DSS). 
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Figure 9.1.5. Butyrate and FBA impair the gut barrier integrity. Real-Time PCR of (A) occludin and (B) zonulin (ZO)-1 in colon 
tissue. Preventive treatment with FBA and curative treatment with butyrate increased mRNA expression of occludin and ZO-1 in colon, 
altered by DSS. Data are mean ± SD from eight mice/group. 
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Butyrate and FBA increase GPR43 expression and distribution along 
intestinal epithelium and induce MCT1 transporter in colonic mucosa 
As depicted in figure 9.1.6 A-B butyrate and FBA, in particular curative protocol, 
were able to increase the transcriptional levels of its main receptor GPR43 and its 
transporter MCT1 compared to control and DSS-untreated mice, suggesting their important 
implication in butyrate anti-inflammatory activity (**P<0.01 vs. CON and #P<0.05 vs. 
DSS). This effect was confirmed by immunofluorecence staining for GPR43. this receptor 
was particularly expressed along intestinal epithelium, and only in DSS-alone group was 
co-localized with PMNs positive cells (data not shown). 
 
   A                                                                       B 
 
Figure 9.1.6. Effect of Butyrate and FBA on GPR43 and MCT1 expression in colon. Real-Time PCR of (A) GPR43 and (B) MCT1 
in colon tissue. Real-Time data are presented as means ± standard error of 5 animals for each group.  
 
Effects of butyrate-based compounds on mucosal infiltration by 
monocytes / macrophages 
Butyrate and FBA reduced monocytes infiltration in colonic mucosa by impairment 
of chemokine expression and lowering macrophages markers. In particular, either 
pharmacological treatments, both preventive and curative protocol, preserved NOS2, CD14 
CD68, Ccl2 enhancement induced by DSS challenge (figure 9.1.7 A-D) (*P<0.05; 
**P<0.01 vs. CON; #P<0.05; ##P<0.01 vs. DSS). 
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Figure 9.1.7. DSS treatment induces up-regulation of monocytes / macrophages markers in colon tissue. Relative amount of (A) 
NOS2, (B) CD14, (C) CD68 and (D) Ccl2 mRNA was significantly increased in DSS-challenged mice treated with vehicle alone. Both 
Butyrate and FBA were able to prevent infiltration of immune cells reducing chemoattractant release in colonic mucosa. Data are 
presented as means ± standard error of 5 animals for each group. 
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9.2 THERAPEUTIC EFFECT OF SODIUM BUTYRATE IN A MODEL 
OF COW'S MILK ALLERGY (CMA) INDUCED IN MICE 
 
Butyrate treatment reduce acute skin response 
As showed in figure 9.2.1 shows the sensitization with BLG led in mice to an 
exacerbated local ear swelling response upon intradermal BLG challenge when compared 
to controls. Daily administration of butyrate significantly reduced the local ear swelling 
response by sensitization (*** P<0.001 vs CON; ## P<0.01 vs BLG). 
 
 
Figure 9.2.1. Acute allergic ear swelling response. sensitization with BLG led to an exacerbated local ear swelling response. butyrate 
significantly alleviated the local response. Data are presented as means ± standard error of 5 animals for each group. 
 
Effect of butyrate oral administration after intragastric challenge 
with BLG 
BLG sensitization also led to a systemic anaphylactic response to intragastric 
challenge with BLG, as assessed by anaphylactic symptom scores (figure 9.2.2 A) and 
body temperature measurement (figure 9.2.2 B). The oral administration of butyrate was 
able to reduce symptom scores and to prevent a decreasing of body temperature after the 
oral challenge with BLG (* P<0.05, *** P<0.001 vs CON; # P<0.05 vs BLG). 
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   A                                                                       B 
 
Figure 9.2.2. Anaphylactic symptom scores. BLG sensitization led to a systemic anaphylactic response to intragastric challenge with 
BLG. The oral administration of butyrate reduces symptom scores (A) and prevents an excessive decreasing of body temperature (B). 
 
Effect of butyrate treatment on immediate immune response 
We determined the concentration of BLG-specific IgE in serum by ELISA assay 
(figure 9.2.3 A), and levels of IL-4 in spleen lysates (figure 9.2.3 B). Butyrate treatment 
significantly decreased both parameters, altered by BLG sensitization (*P<0.05 vs CON 
and vs BLG). 
 
   A                                                                     B 
 
Figure 9.2.3. BLG-specific IgE (A) and IL-4 (B) measurement.. Butyrate significantly decreased both parameters, altered by BLG 
sensitization. 
Butyrate treatment restored intestinal permeability increased by BLG 
sensitization 
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Finally, we demonstrated that BLG sensitization increased gut permeability, 
measured trough the detection of DX-4000 FITC in plasma, compared to control group. 
Butyrate was able to remarkably improve the intestinal barrier integrity (figure 9.2.4) 
(*P<0.05 vs CON and vs BLG). 
 
 
Figure 9.2.4. Intestinal permeability to plasma DX-4000 FITC. BLG sensitization increases gut permeability. 
Butyrate improves the intestinal barrier integrity. 
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9.3 ANTI-INFLAMMATORY EFFECT OF SODIUM BUTYRATE AND 
ITS CHEMOATTRACTANT ACTIVITY MEDIATED BY GPR43 
RECEPTOR IN MURINE CHONDROCYTE CELL LINE 
 
Butyrate decreases IL-1-induced NO production but not cell viability 
ATDC5 chondrogenic cells were stimulated with 0,5 ng/ml IL-1 in the absence or 
presence of increasing concentrations of sodium butyrate (10-250 µM) and the production 
of NO was evaluated using Griess reagent. The treatment with butyrate marked decreased 
IL-1-induced nitrite amount in a concentration-dependent manner (figure 9.3.1 B) 
(***P<0,001 vs CON; #P<0,05; ##P<0,01 vs IL-1). The observed inhibition was not due to 
the reduction of cell viability as confirmed by the methyl thiazolyl tetrazolium (MTT) 
assay (figure 9.3.1 A). 
    A                                                                             B 
 
Figure 9.3.1. Cell viability assay and nitrite accumulation. The treatment with butyrate marked decreased IL-1-induced nitrite amount 
(B) in a dose-dependent manner but not cell viability (A). Data are presented as means ± standard error of 3 different experiments. 
 
Butyrate reduces pro-inflammatory mediators and adipokines in 
chondrocytes stimulated by IL-1 
Consistently with the reduction of NO accumulation, we evaluated the effect of 
butyrate treatment on mRNA expression of NOS-2, Ptgs2 and Interleukin-6, analyzed by 
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real time PCR. The relative expression level of each gene mRNA was plotted as fold 
changes versus untreated control cells. GAPDH gene expression was used for 
normalization. Under basal conditions, Nos2, Cox2 and Il-6 levels were undetectable, 
while IL-1 stimulation induced a significant increase of all gene mRNA levels. Butyrate at 
the dose of 250 µM was able to suppressed markedly this induction, suggesting that the 
anti-inflammatory effect of butyrate was at transcriptional level (figure 9.3.2 A-C-D) 
(***P<0,001 vs CON; ###P<0,001 vs IL-1). Next, we analyzed the iNOS protein by 
Western blotting and butyrate significantly reduced this expression, induced by IL-1 
challenge (figure 9.3.2 B) (***P<0,001 vs CON; ##P<0,01 vs IL-1).  
We also examined lipocalin-2 (LCN2) and nesfatin-1 (or NUCB2) production in 
response to IL-1 stimulation showing a significant increase of both genes mRNA 
expression compared with control. In contrast, the treatment with butyrate markedly 
decreased LCN2 and NUCB2 (figure 9.3.2 E-F) (***P<0,001 vs CON; ### P<0,001 vs IL-
1). 
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Figure 9.3.2. Expression of pro-inflammatory cytokines and adipokines in murine chondrocytes. IL-1 stimulation induced a 
significant increase of Nos2 (A-B), Ptsg2 (C) and Il-6 (D) expression. Butyrate at the dose of 250 µM was able to suppressed markedly 
this induction. Butyrate also reduces the expression of pro-inflammatory adipokines lipocalin-2 (E) and NUCB2 (F). 
Western blot and Real Time data  are presented as means ± standard error of 3 different experiments. 
 
Butyrate reduces adhesion molecules expression 
The vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 
(ICAM-1) proteins mediate the adhesion of lymphocytes, monocytes, eosinophils, and 
basophils to vascular endothelium and may play a role in the development of 
atherosclerosis and rheumatoid arthritis. Here, we showed that, upon IL-1 stimulation, the 
mRNA levels of these molecules were deeply increased (figure 9.3.3 A-B-C). 
(***P<0,001 vs CON; ### P<0,001 vs IL-1). Similarly, the protein expression of VCAM-1 
was markedly increased. Butyrate treatment, 1 h before IL-1 stimulation until 24 h, was 
able to significantly reduce these levels. 
 
Effect of butyrate on pro-inflammatory and anti-apoptotic pathways 
in ATDC5 cells 
In response to inflammatory stimulation the p65 subunit of Nfκ-B is activated and 
translocates in the nucleus and in the same time IκB-α is degraded in cytoplasm. In our 
experiments on ATDC5 cells, after IL-1 stimulation for 15-30 minutes, the activation of 
p65 subunit and consequently IκB-α degradation were induced and evaluated by Western 
blotting in nucleus and cytoplasmic lysates, respectively. Butyrate significantly reduced 
88 
 
NFκB p65 expression in nucleus and consistently increased IκB-α in cytoplasm (figure 
9.3.4 A-B). Moreover, it is well known that mitogen-activated protein (MAP) kinase 
pathway is involved in the inflammatory response. Here, we showed that butyrate 
significantly decreased the phosphorylation of p44/42 MAPK (or 44/42 ERK) and of p38 
subunit, significantly activated by IL-1, suggesting that its anti-inflammatory effect 
involved MAP-kinase cascade signaling (figure 9.3.4 C-D). 
AMPK is currently known to act as a key regulator of metabolic homeostasis. In fact, 
several biosynthetic enzymes for fatty acid or glycogen are recognized as targets of 
AMPK. It was well known that IL-1 induces phosphorylation of AMPK-α, which regulates 
AMPK activities [344]. Also in chondrocytes the phosphorylation of AMK- α was 
significantly increased by IL-1 stimulation compared with no-treated cells, while sodium 
butyrate markedly reduced this phosphorylation, inducing AMPK-mediated anti-
inflammatory activity (figure 9.3.4 E). At the same time, butyrate acted on anti-apoptotic 
phosphatidylinositol 3-Kinase/Akt pathway, that is activated by inflammatory stimulation 
[345]. Consistently, we demonstrated that IL-1 induced an increase of Akt 
phosphorylation, which was remarkably reduced by butyrate treatment, as shown by 
Western blot analysis (figure 9.3.4 F), suggesting its involment also in regulating the 
phosphatidylinositol 3-kinase/Akt pathway in inflammation (*P<0,05 vs CON, 
***P<0,001 vs CON; ### P<0,001 vs IL-1). 
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Figure 9.3.3. Expression of VCAM-1 and ICAM-1 after IL-1 stimulation. Upon IL-1 stimulation, the mRNA levels of these 
molecules (A and C) and, ssimilarly, the protein expression of VCAM-1 (B) were greatly increased. Butyrate significantly reduced these 
levels. Real-Time and Western blot data are presented as means ± standard error of 3 different experiments. 
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Figure 9.3.4. Effect of butyrate on pro-inflammatory pathways. After IL-1 stimulation for 15-30 minutes, the translocation of p65 
subunit and IκB-α degradation were induced. Butyrate significantly reduced p65 expression in nucleus and increased IκB-α in cytoplasm 
and significantly decreased the phosphorylation of p44/42 MAPK (or 44/42 ERK) (A) and of p38 subunit (B), activated by IL-1. Also 
butyrate was able to reduce the phosphorylation of AMKα (E)and of Akt (F) significantly induced by IL-1 stimulation. Western blot data 
are presented as means ± standard error of 3 different experiments. 
 
Butyrate suppresses MMP-13 production and increases collagen type 
II levels after inflammatory stimulation 
Cartilage destruction in OA is thought to be mediated mainly by MMPs family, 
which are responsible for cartilage collagen breakdown. For this reason, we studied the 
effect of butyrate on MMP-13 expression induced by IL-1. Cytokines stimulation produced 
a marked increase of MMP-13 expression and consistently a reduction of collagen type II 
levels. Butyrate (250 µM) resulted in suppressing MMP13 mRNA expression and 
increasing collagen type II (figure 9.3.5 A-B) (***P<0,001 vs CON; ### P<0,001 vs IL-1). 
 
Figure 9.3.5. MMP13 and collagen tyoe II mRNA levels. Cartilage destruction in the osteoarthritis is mediated mainly by the matrix 
MMPs. Sodium butyrate (250 µM) resulted in suppressing MMP13 mRNA expression (A) and in increasing collagen type II (A) levels. 
Real-Time and Western blot data are presented as means ± standard error of 3 different experiments. 
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Butyrate induces chemokines recruitment after several inflammatory 
challenges 
 
In chondrogenic cells, IL-1 stimulation induced mRNA of important chemokines involved 
in inflammatory process and in neutrophils and leucocytes recruitment, such as Ccl3 and 
Cx3cl1, and it induced the activation of annexin-1 (AnxA1), also known as lipocortin, a 
protein that inhibits various inflammatory events, including chemotaxis (figure 9.3.6 A-C-F).  
Interestingly, butyrate showed a chemoattractant effect in ATDC5 cells, increasing 
significantly mRNA expression of these genes. Behind anti-inflammatory effect of butyrate, 
this activity supports its capability to modulate immune response as pro-resolving factor in 
inflammation, due to the chemokine increase and resolvin induction (figure 9.3.6 A-C-F). 
(***P<0,001 vs CON; ###P<0,001 vs IL-1). 
To demonstrate that the chemoattractant effect of butyrate was independent by the type of 
inflammatory challenge, we treated ATDC5 cells with other two inflammatory stimuli such as 
LPS (1 ng/mL) and TNF-α. The cells were pre-treated for 1 hour with sodium butyrate (250 
µM) and for 24 hours with challenges; then the expression of Ccl3 and Cx3cl1was evaluated. 
These parameters were markedly increased by both stimulations and butyrate confirmed its 
chemoattractant effect, suggesting a general cross-section mechanism as pro-resolving factor 
(figure 9.3.6 B-D-E) (***P<0,001 vs CON; ### P<0,001 vs IL-1). 
 
Anti-inflammatory effect of butyrate in mature chondrocytes after 
differentiation 
Anti inflammatory effect of butyrate was confirmed in mature chondrocytes, after 
IL-1 stimulation (figure 9.3.7). After 14 days of ATDC5 cell differentiation, butyrate 
treatment of mature chondrocytes significantly reduced inflammatory enzymes and 
adipokines, also limiting the loss of collagen type 2 and inducing chemokine recruitment 
and resolving factor AnxA1 (figure 9.3.7) (***P<0,001 vs CON; ### P<0,001 vs IL-1). 
 
92 
 
 
 
Figure 9.3.6. Effect of butyrate on immune response to inflammatory process induced by IL-1. IL-1 stimulation induced 
neutrophils and leucocytes recruitment, increasing Ccl3 (A) and Cx3cl1 (C) levels and induced the activation of annexin-1 (F). Butyrate 
showed a chemoattractant effect, increasing significantly mRNA expression of these genes. After both LPS and TNF-α stimulation (B-
D-E), butyrate showed its chemoattractant effect, suggesting a possible general mechanism as pro-resolving factor. Real-Time data are 
presented as means ± standard error of 3 different experiments. 
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Figure 9.3.7. Effect of butyrate on inflammatory response in mature chondrocytes. After 14 days of cell differentiation, butyrate 
significantly reduced inflammatory cytokines (A-B) and adipokines (C), and limited the loss of collagen type 2 (D) induced by IL-1, 
confirming its anti-inflammatory activity during the differentiation. Butyrate also was able to act as pro-resolving factor, increasing 
Cx3cl1 (E) and AnxA1 (F) levels. Real-Time data are presented as means ± standard error of 3 different experiments.
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GPR43 receptor mediates chemoattractant effect of butyrate in 
ATDC5 cell line 
To clarify a possible mechanism of butyrate chemoattractant effect we hypothesized that it 
was modulate by GPR43, the main butyrate receptor. To this purpose we silenced GPR43 
gene in ATDC5 cells for 48 hours and then mRNA was extracted and chemokine 
expression was evaluated. The chemoattractant effect of butyrate after IL-1 stimulation 
was significantly inhibited and reverted by GPR43 silencing, leading to a significant 
reduction of Cx3cl1 and AnxA1 transcriptional levels, as shown in figure 9.3.8 A-B. This 
result suggests the direct implication of this receptor in modulating butyrate 
chemoattractant activity (***P<0,001 vs CON; ### P<0,001 vs IL-1).  
 
 
Figure 9.3.8. Chemoattractant actvitiy of butyrate mediated by its receptor GPR43. siRNA-mediated gene silencing of GPR43 
receptor for 48 hours in ATDC5 cells. The chemoattractant effect of butyrate on Cx3cl1 (A) and AnxA1 (B) was inhibited by Gpr43 
silencing. Real-Time data are presented as means ± standard error of 3 different experiments. 
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9.4 THERAPEUTIC EFFECT OF BUTYRATE AND ITS 
DERIVATIVE FBA IN ANIMAL MODELS OF WOUND 
HEALING INDUCED BY DOXORUBICIN OR 
MECHANICAL DAMAGE 
 
Effect of butyrate and FBA on doxorubicin-induced wound healing 
As previously described [342], standardized skin ulceration was performed by intradermal 
injection of 2 mg/ml doxorubicin solution on the shaved dorsum of male Sprague-Dawley 
rats. The maximum of skin ulcer area was reached 11 days after drug injection. The lesion 
size was measured at day 1, 5, 10, 14 and 21 by using ImageJ software. We showed that 
the oral treatment with sodium butyrate (20 mg/Kg) and its derivative FBA (42.2 mg/Kg) 
remarkably reduced the skin ulcer area compared with control group. Pictures and wound 
area graphic confirmed butyrate effect (figure 9.4.1 A-B) (*P<0,05, **P<0,01 and 
***P<0,001 vs CON). 
 
     A 
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Figure 9.4.1. Determination of wound resolution time. The maximum of skin ulcer area was reached 11 days after doxorubicin 
injection. The lesion size was measured at day 1, 5, 10, 14 and 21 by using ImageJ software. The oral treatment with sodium butyrate  
and FBA remarkably reduced the skin ulcer area, as shown by pictures (A) and wound area graphic (B). 
 
Sodium butyrate and FBA promote the excising-induced wound 
healing 
We confirmed the beneficial effect of butyrate in another model of wound healing 
induced by mechanical damage. For this reason we created a full thickness middorsal 
wound by excising the skin and the underlying panniculus carnosus with bioptic 
instrument. Wound closure was measured after 3, 7 and 14 days and to evaluate the change 
of the wound area for each mouse, we took a picture of wound and analyzed using ImageJ 
software. We showed that the subcutaneous treatment with sodium butyrate (1-10 μg), and 
more with its derivative FBA (1-10 μg), was able to significantly accelerate the wound 
healing compared with control mice, as shown by pictures and wound area analysis in 
figure 9.4.2 A-B (*P<0,05, **P<0,01 and ***P<0,001 vs CON). 
Further study will be needed to determine the mechanism by which butyrate could 
act independently by route of administration. 
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Figure 9.4.2. Evaluation of wound healing during the time after excising. Wound closure was measured after 3, 7 and 14 days, using 
ImageJ software. The subcutaneous treatment with sodium butyrate and FBA significantly accelerated the wound resolution, 
as shown by pictures(A) and wound area analysis (B). 
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10. DISCUSSION 
10.1 N-(1-CARBAMOYL-2-PHENYL-ETHYL) BUTYRAMIDE, A 
NEW SYNTHETIC BUTYRATE DERIVATIVE, REDUCES 
INTESTINAL INFLAMMATION IN DEXTRAN SODIUM 
SULPHATE-INDUCED COLITIS. 
 
Despite the wide spectrum of possible indications, the major limits of butyrate in 
clinical practice are its unpleasant taste and odour, when orally administered, or 
discomfort, by rectal preparations. 
In this study we demonstrated that Butyrate and its derived amide FBA are able to 
protect from colitis injury induced by DSS administration in mice. In particular, they play 
their effects restoring epithelial barrier integrity and reducing colon inflammation.  
The efficacy of derivative FBA, compared to butyrate, was evaluated in an animal 
model of colitis induced by DSS. 
Even if dietary fiber intake, leading to SCFA production, has shown benefits in IBD 
[218, 346, 347], other data had demonstrated an inverse association between intake of 
fruits and vegetables and risk of IBD [348] and more recently dietary intake and risk of 
developing IBD have been reviewed [349, 350]. Very recently the rational identification of 
diet-derived postbiotics in restoring intestinal microbiota composition and function has 
been reviewed [351]. For all these reasons the use postbiotics, such as butyrate, may be a 
potential alternative to the use of live probiotic organisms or dietary fiber intake as 
prebiotics. In fact, the beneficial effects of sodium butyrate in different models of DSS-
induced colitis in mice have been already reported after oral or topical administration [215, 
216]. 
In our experiment, DSS mice showed a reduction of body weight after five days of 
DSS administration, while both butyrate-based treatments (PREV and CUR) reduced this 
loss in DSS-challenged mice. Our results on mice weight change were comparable to those 
shown in other DSS induced models of colitis [352, 353]. The clinical and histological 
changes were determined by phenotypic and pathologic changes, such as diarrhea, rectal 
bleeding, body weight loss and colon shortening, which were the common phenomena seen 
in DSS-induced experimental colitis. Diarrhea is due to the increased permeability of 
epithelium or hyper-osmolarity in lumen led by DSS [354]. Weight loss and colon 
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shortening, as indicators for the severity of intestinal inflammation, correlate with the 
pathologic and histological changes and are consistent markers for colitis. 
Here, we tested oral FBA efficacy in DSS colitis characterized by a significant loss 
of body weight, associated to diarrhea, rectal bleeding and colon shortening. These 
phenotypic and pathologic changes were counteracted by FBA, and similarly by sodium 
butyrate, especially when used as therapeutic protocol. 
In this experimental model, establishment of inflammation and tissue injury in DSS-
challeged mice was confirmed by the increase in colon tissue of nitric oxide synthase-2 
(NOS2), TNF-α, IL-6 and IFN? and by the reduction in colonic mRNA levels of IL-10 and 
PPAR? and in serum adiponectin. IL-10 plays an important role in preventing colitis 
pathology. In fact, IL-10 knockout mice are prone to develop spontaneous colitis [355]. 
Anti-inflammatory effect of preventive and curative treatments with butyrate or FBA was 
also evident in reducing pro-inflammatory mediators and in restoring anti-inflammatory 
ones. In spite of its clinical beneficial effects for patients suffering from IBD [356], there is 
a lack of understanding of how SCFAs exert their anti-inflammatory effects. Recent 
studies of Chang et al. [357] demonstrate that the short chain fatty acid n-butyrate, which is 
secreted in high amounts by commensal bacteria as Clostridiales species, can modulate the 
function of intestinal macrophages, the most abundant immune cell type in the lamina 
propria. In fact, treatment of macrophages with n-butyrate led to the downregulation of 
LPS-induced pro-inflammatory mediators, including nitric oxide, IL-6, and IL-12, but did 
not affect levels of TNF-α or MCP-1. The authors attributed these effects to inhibition of 
HDAC activity in macrophages, as it is known that SCFAs inhibit HDAC activity in many 
cell types [358].  
Butyrate regulates epigenetically gene expression by inhibiting HDAC, specifically 
class IIA and I [359], and its anti-inflammatory effects are related to this mechanism in 
many cell types [357]. In particular class IIA HDAC has been reported to suppress 
regulatory T cells (Tregs) expansion [358] and the inhibition of HDAC9 increases Treg 
function, reducing colitis in mice [360]. Through HDAC inhibition, butyrate could avoid 
NF-κB activation in human colonic epithelial cells (CECs) [99]. NF-κB regulates many 
cellular genes involved in early immune inflammatory response frequently dysregulated in 
IBDs [361]. Here, FBA reproduced the same effect of butyrate, limiting the Hdac9 
transcript up-regulation induced by DSS challenge. Accordingly, FBA and butyrate, 
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especially when used as therapeutic treatment, inhibit NF-κB activation and promote 
histone H3 acetylation. 
 NF-κB regulates many cellular genes involved in early immune inflammatory 
responses, including IL-1β, TNF-α, IL-2, IL-6, IL-8, IL-12, NOS2, COX-2, ICAM-1, 
VCAM-1, TCR-α, and MHC class ? molecules [97]. The activity of NF-κB is frequently 
dysregulated in colon cancer [98] and in IBDs, such as ulcerative colitis and Crohn’s 
disease [99, 100]. So, we can hypothize that one of the possible mechanisms of action 
underlining its anti-inflammatory effects is linked to butyrate and FBA ability in 
preventing or reducing NF-κB activation by HDAC9 inhibition. 
These findings not only link butyrate to commensal microbe-mediated induction of 
functional T-reg cells in the colonic mucosa, but also provide molecular insight into the 
therapeutic application of butyrate, indicating how a metabolite produced by colonic 
microbial fermentation mediates host–microbial crosstalk for the establishment of gut 
immune homeostasis [362]. Numerous studies have reported that butyrate metabolism is 
impaired in intestinal inflamed mucosa of patients with IBD. Recent data show that 
butyrate deficiency derives from the reduction of butyrate uptake by the inflamed mucosa 
through downregulation of MCT1 [105]. Butyrate transport deficiency is expected to have 
clinical consequences. Particularly, the reduction of the intracellular availability of butyrate 
in colonocytes may decrease its protective effects on cancer in IBD patients [214]. So, in 
our model we observed a strong reduction of this transporter in colonic mucosa of DSS 
mice, confirming an impairment of butyrate utilization, and oxidative stress, in 
colonocytes. Both butyrate and FBA, only when applied alongside a curative protocol, 
prevented this down-regulation restoring MCT1 transcription to physiological levels. Aside 
from inhibition of NF-kB activation, butyrate may exert an anti-inflammatory activity 
through the up-regulation of PPAR-γ [361, 363]. This nuclear receptor is a ligand-activated 
transcription factor highly expressed in colonic epithelial cells, whose activation induces 
anti-inflammatory effects [364]. Our hypothesis is that butyrate up-regulates PPAR-γ in 
epithelial cells, where this acts in a negative feedback loop, uncoupling NFkB –dependent 
target genes, involved in the inflammatory response [365]. In fact, butyrate and FBA 
restored PPAR-γ mRNA levels in colonic mucosa, reducing cytokines release and 
inflammatory status and improving intestinal homeostasis. 
IBDs are also thought to result from inappropriate and ongoing activation of the 
mucosal immune system driven by penetration of normal luminal flora due to tight-
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junction defects of the intestinal epithelial barrier. Our results showed a protective effect of 
butyrate and FBA in restoring transcriptional levels of two major tight junctions as 
occludin and ZO-1. These data demonstrate that butyrate has a noticeable effects on 
colonic epithelial integrity and physiology. The altered TJ structure in ulcerative colitis 
results in impaired barrier function, which may lead to increased uptake of luminal 
antigens and/or adjuvants that overwhelm the net suppressive tone of the mucosal immune 
system [366]. SCFAs modulate key epithelial cell functions that help to maintain intestinal 
epithelial barrier integrity against injury [367]; The most important effect of gut 
permeability integrity is the reduction of bacterial translocation and maintenance of 
mucosal immunity homeostasis. In fact DAMPs release and PAMPs penetration determine 
a strong recruitment of immune cells in infection site and subsequent inflammation 
establishment. FBA showed an higher effect than that of butyrate in restoring 
transcriptional levels of Ocln and Tjp1.  
In this study, we also show that butyrate and FBA up-regulated GPR43 mRNA levels 
in colonic mucosa. Moreover, we confirmed the involvement of this receptor in neutrophil 
recruitment. Indeed, GPR43 was co-localized with neutrophil cells only in DSS-challenged 
mice (data not shown). These data suggest that in inflammatory conditions GPR43 can 
regulate neutrophil chemotaxis (figure 10.1.1), while butyrate and FBA treatments, 
improving intestinal barrier integrity and reducing immune cells recruitment, are able to 
increase GPR43 expression only on intestinal enteroendocrine L cells . Taken together 
these actions, both butyrate-based compounds displayed anti-inflammatory properties.  
Butyrate and FBA reduced transcriptional levels of Ccl2 gene, which encodes for 
MCP-1, in colon tissue and thus could impair monocyte recruitment as confirmed by 
reduced CD68 and CD14 mRNAs, both markers of macrophages. Besides, both butyrate-
based compounds, as demonstrated in another experiment, down-regulated AnxA1, Fpr1 
and Fpr2 mRNA levels, reducing PMN infiltration (data not shown). 
 
Conclusions 
 
In conclusions these data show that butyrate and FBA are able to attenuate colitis and 
colon injury, reducing the inflammatory response via gut integrity improvement, and 
suppression of neutrophil recruitment in colon tissue. Both compounds restore PPAR-γ 
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levels and block NF-kB activation, leading to colonocyte protection from inflammation. In 
addition, gut integrity is improved, avoiding bacterial translocation and limiting immune 
cell recruitment. These anti-inflammatory effects are visible as reduction in neutrophil 
infiltration and HDAC9 transcription in colonic mucosa and as modulation of butyrate 
transporter and receptor. These events improve intestinal immune homeostasis and 
tolerance vs. commensal bacteria. The efficacy of butyrate in limiting early molecular 
events responsible of the inflammatory process linked to the intestinal damage suggests its 
potential clinical utility as a preventive or therapeutic strategy for UC.  
 
 
Figure 10.1.1. GPR43 involvement in inflammation and immune system modulation.  
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10.2 THERAPEUTIC EFFECT OF SODIUM BUTYRATE IN A 
MODEL OF COW'S MILK ALLERGY (CMA) INDUCED IN MICE 
 
In the experimental model of CMA, we show the therapeutic effect of oral sodium 
butyrate administration in suppressing acute skin response to the allergen BLG and in 
reducing anaphylactic symptoms and immediate immune response. Moreover, butyrate is 
able to restore gut integrity, compromised by BLG sensitization. 
The Centers for Disease Control reported that the prevalence of food allergy 
increased from 3.4% to 5.1% between 1997 and 2011 in the United States [219]. To 
understand which factors might be driving this increase, attention has turned to the trillions 
of bacteria that populate human gastrointestinal tract, known collectively as gut microbiota 
[368]. Recent environmental interventions, including widespread antibiotic use, 
consumption of a high fat/low fiber Western diet, elimination of previously common 
enteropathogens (including H. pylori and helminthic parasites), increased 
vaccination/reduced exposure to infectious disease, and Caesarean birth/formula feeding 
have perturbed mutually beneficial interactions established with commensal microbiota 
over millions of years of co-evolution. In genetically susceptible individuals, this dysbiosis 
can predispose to both allergic and chronic inflammatory diseases [369]. The National 
Institute of Allergy and Infectious Diseases also defined food allergy as ‘‘an adverse health 
effect arising from a specific immune response that occurs reproducibly on exposure to a 
given food’’ and food intolerance as no immune reactions that include metabolic, toxic, 
pharmacologic, and undefined mechanisms [370]. 
Animal models of food allergy have emerged as tool for identifying mechanisms 
involved in the development of sensitization to normally harmless food allergens, as well 
as delineating the critical immune components of the effect or phase of allergic reactions to 
food [371]. However, animal models might play a role in understanding human unclear 
diseases. 
Interestingly, allergy is a field in which the transcriptional analysis approach has 
shown remarkable consistency between murine and human species. For example, a recent 
study using a murine model of atopic dermatitis (AD) included comparisons with data 
from affected human skin and showed a high degree of homology in the gene expression 
profile [372]. Also the choice of a specific animal strain is important. Using genetically 
modified mice, the authors definitively showed key roles for T cells and mast cells in 
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disease pathogenesis. Similarly, in a murine model of severe asthma, Yu et al [373] 
performed transcriptional comparison analysis between the murine lung and human lung 
biopsy specimens. Their data showed a highly significant association in gene expression 
patterns that was lost in mast cell–deficient mice, but restored if mast cells were 
reconstituted by adoptive transfer. There is no doubt that such validation approaches will 
be an important aspect of mechanistic studies moving forward. 
The review by Oyoshi et al. [371] aimed to outline the role that animal models 
might play in understanding the potential mechanisms of pathogenesis in food allergy, as 
well as to highlight how animal models might contribute to the development of future 
therapies. There are generally 3 main types of approach in modeling human disease: 
homologous (in which the underlying cause, symptoms, and treatments are shared), 
isomorphic (in which the symptoms and treatments are shared), and predictive (in which 
symptoms might be different but treatments show efficacy). Within the allergy field, most 
models are isomorphic. 
In the field of food allergy, there is not enough information regarding the nature of 
food allergens and the mechanisms responsible for loss or lack of tolerance in patients. 
However, it is important to note that food allergens to mice elicits oral tolerance, as it 
occurs in most human subjects. Instead, mucosal adjuvants, such as cholera toxin (CT) 
[374] or staphylococcal enterotoxin B (SEB) [375, 376] or genetically manipulated mouse 
strains susceptible to enteral sensitization [230] have been used. In our study, we used CT 
as allergy adjuvant in all sensitizations with BLG (20 mg/ml) ad day 1, 7, 14, 21 and 28, 
and at day 35 with BLG oral challenge (50 mg/ml). 
One of the critical advantage of using mouse models to study food allergy is that 
allergic sensitization or tolerance can be induced to specific allergens under controlled 
environmental conditions within defined genetic backgrounds, which is not possible in 
human subjects. This aspect of mouse models allows extensive and precise investigations 
into the mechanisms involved in disease etiology or therapy, such as identification of 
possible triggers, as well as pathways involved in food allergy. Normally, ingestion of food 
results in oral tolerance in mice, as in most human subjects. 
Increasing evidence from mouse models indicates that alterations in regulatory T 
(Treg) cell function and environmental factors, such as microbiota, are likely important 
contributors to allergic sensitization and food allergy, although the immune mechanisms 
responsible for breakdown in oral tolerance are not fully understood. Enteral sensitization 
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to food allergens can also be elicited in the absence of CT or SEB in mice genetically 
manipulated to enhance IL-4 responses. For instance, Il4raF709 mice, in which IL-4 
signaling is enhanced because of disruption of the inhibitory signaling motif in the IL-4 
receptor ?-chain, exhibit sensitization to food proteins, mast cell expansion, anaphylactic 
responses after food challenge, and a food allergy–specific gut microbiota. [230, 231, 377]. 
These findings implicate strong IL-4 signals, such as those that might be encountered in 
the TH2 milieu of atopic patients, in subverting Treg cell responses to oral antigens and 
fostering the development of food-specific IgE, intestinal mast cell expansion, and 
susceptibility to anaphylaxis. Consistently, in our experiment we showed that the 
sensitization with the allergen BLG increased IgE levels in serum and IL-4 content in 
spleen lysates. 
Moreover, increased intestinal permeability has been suggested as a potential cause 
of food allergy , possibly through increased exposure to the intact protein. In our 
experiments, we demonstrated that the sensitization with BLG affected gut barrier 
integrity, while the treatment with butyrate was able to limit the increase of intestinal 
permeability and, consequently, to improve gut integrity. 
Moreover, alterations in the microbiota have been implicated in the pathogenesis of 
atopic dermatitis (AD), asthma, and food allergy [229]. Intestinal microbiota influences the 
network of the immune system and results in impaired regulatory functions and TH2 
skewing. While germ-free (GF) conditions are almost impossible in human studies, 
limiting the types of analysis that can be performed, a role for commensal microbiota in 
promoting oral tolerance has been clearly defined by using gnotobiotic mice, in which 
reconstitution of GF mice with well-characterized communities of microbiota or defined 
bacteria has been performed. Numbers of CD41 Foxp31 Treg cells are reduced in 
antibiotic-treated mice or GF mice [378, 379], which exhibit a predisposition toward 
allergic sensitization [379, 380].  
Administration of defined commensal microbiota, such as Clostridia species and 
Bacteroides fragilis, or SCFAs to GF mice induced Treg cells [358, 378, 381, 382] and 
reduced allergic sensitization [378], supporting the notion that intestinal commensal 
microbiota promotes Treg cells and limits allergic responses to foods.  
To this purpose, we have clearly demonstrated that the oral administration of sodium 
butyrate before and during sensitizations with BLG was able to significantly reduce the 
acute skin response to this allergen and to markedly decrease the innate immune response, 
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leading to the suppression of allergic responses to BLG, one of the most important cow’s 
milk proteins. 
 
Conclusions 
 
In conclusion, in our experimental model we demonstrate that the oral administration 
of sodium butyrate before and during sensitization with the allergen BLG is able to reduce 
acute allergenic response, decreasing of ear swelling and hypersensitivity symptoms and 
limiting the decrease of body temperature. Butyrate treatment also significantly decreases 
the innate immune response, reducing IgE and IL-4 levels, measured in plasma and spleen 
lysates respectively. Finally, butyrate is able to restore intestinal barrier integrity altered by 
BLG. Efficacy of sodium butyrate in limiting acute and immune allergenic response can 
suggest its clinical application as a therapeutic strategy for the treatment of cow’s milk 
protein allergy, especially in children. 
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10.3 IN VITRO ANTI-INFLAMMATORY EFFECT OF SODIUM 
BUTYRATE AND ITS CHEMOATTRACTANT ACTIVITY 
MEDIATED BY GPR43 RECEPTOR IN CHONDROCYTE 
 
In this in vitro study, we demonstrated the anti-inflammatory effect of sodium 
butyrate in reducing inflammatory mediators and pathways in chondrocytes activated by 
IL-1, and, more interestingly, that butyrate chemoattractant activity is mediated by its 
receptor GPR43. 
It is well known that OA is the most common form of arthritis worldwide, whose 
development is increased by aging, obesity and biomechanical injury [383]. The central 
characteristic of OA is a progressive degeneration of cartilage, which leads to permanent 
functional joint failure and disability, but it also involves the whole synovial joint organ 
[383].  
OA is related to degenerative disease in which chondrocytes play a central role , 
because in this pathology chondrocyte phenotype changes and apoptosis and extracellular 
matrix degradation occur [279, 384]. 
Here, we have demonstrated that after 24 hours of IL-1 (0,5 ng/ml) stimulation the 
nitrite production is increased. Our experiments are in agreement with other studies 
showing that all severe perturbations previously described in cartilage homeostasis result 
to be mediated by nitric oxide, an important mediator induced by several pro-inflammatory 
cytokines, including IL-1 which plays a central role in the pathophysiology of OA [385]. 
Butyrate treatment is able to limit nitrite accumulation, suggesting its involvement in 
maintaining and regulating cartilage homeostasis. 
Moreover, some evidences clarify that the role of inflammation is pivotal in OA 
[247], and recognized through the association of joint effusion with joint pain [248] and 
significant production of several pro-inflammatory mediators [279, 386, 387]. Indeed, we 
showed that IL-1 stimulation markedly increased the expression of iNOS, COX-2 and IL-
6. According to our findings, some studies showed that OA severity and progression 
depend on the concentration of key SF cytokines, such as IL-1, IL-18 and TNF-??[250, 
255]? In particular, IL-1? induces a cascade of inflammatory and catabolic events in 
chondrocytes, including the synthesis of prostaglandin E2 (PGE2) and NO [313]. At the 
same time, also adipokine dysregulation is a clear component of metabolic triggered 
inflammation that appears to play a major role in OA and RA [388, 389]. In particular, 
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lipocalin-2 was found in human and murine chondrocytes; and highly expressed in 
hypertrophic chondrocytes [390, 391]. It is modulated by several factors, including IL-1β 
[390-393] and increased in different rheumatic diseases, especially OA [394] and inflamed 
cartilage results highly positive for this adipokine . Similarly, Li et al. [395] showed that 
nesfatin-1 (or NUCB2) increased bone mineral density of ovariectomized rats, suggesting a 
pro-osteogenic activity of this adipokine, that would represent a valuable treatment of bone 
metabolic diseases, such as osteoporosis. For this reason and for its strong similarities in 
terms of metabolic actions with other members of adipokine superfamily, NUCB2 was 
found to be involved in rheumatic disorders, such as OA and associated inflammation 
[396]. 
Consistently with all these data, we investigated the expression of LCN2 and 
nesfatin-1/NUCB2 in ATDC5 cell line after IL-1 stimulation and simultaneous treatment 
with butyrate for 24 hours and we demonstrated that their expression is highly induced by 
IL-1. Interestingly, butyrate is able to reduce the levels of both pro-inflammatory 
adipokines. 
It is well known that the recruitment of circulating leukocytes to sites of 
inflammation is facilitated by adhesion molecules [397]. For example, stronger attachment 
of leukocytes to endothelium is mediated by ICAM-1 and VCAM-1 [397] and these cell 
adhesion molecules are commonly more detected in human atherosclerotic lesions than in 
healthy arterial tissue [398, 399] and their expression is regulated by pro-inflammatory 
cytokines [397, 400]. In our conditions, IL-1 stimulation increased expression of VCAM-1 
and ICAM-1, that was reduced by sodium butyrate. 
In articular chondrocytes, IL-1β is able to trigger several signaling cascades, as that 
of MAP-kinases [401], which may activate consequentially the DNA binding activity of 
NF-κB and AP-1. It has been showed that high NF-κB and AP-1 binding activity has been 
found in the synovium of patients with RA and OA, pointing out their involvement in 
disease pathogenesis [401]. Consistently with these findings, in our study we demonstrated 
that IL-1 stimulation causes a marked increase of NF-κB p65 migration in the nucleus. 
Butyrate not only significantly reduced NF-κB activation, also limiting IκB-α degradation. 
In addition, we clearly demonstrated butyrate-induced inhibition of MAP-kinase pathway, 
altered by inflammatory stimulus. Other studies have demonstrated that many pro-
inflammatory genes transcription is mediated by NF-κB [402, 403] and sequential 
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activation of important cytoplasmic protein kinases, such as MAPKs (ERK1/2 and p38, in 
particular) [404, 405].  
Moreover, it was clearly showed that IL-1 activated anti-apoptotic 
phosphatidylinositol 3,4,5-trisphosphate (PI3) -kinase/Akt pathway and induced the anti-
apoptotic effects of Akt [345]. Certain inhibitors of PI 3-kinase blocked ERK activation, 
suggesting a regulatory role for the PI 3-kinase pathway in the MAPK cascade [406, 407]. 
In agreement with these data, we demonstrated that IL-1 stimulation increases the 
phosphorylation of Akt, while butyrate blocks this activation, leading to a remarkable 
decrease of Akt anti-apoptotic effect, paralleled by the reduction of ERK1/2 
phosphorylation. 
Furthermore, IL-1? and hydrogen peroxide led to an activation of the redox 
dependent transcription of NF-κB and AP-1 in bovine chondrocytes [408, 409], triggering 
a remarkable decrease in type II collagen transcription, associated with a significant 
increase in MMP synthesis. Moreover, Terkeltaub et al. [410] showed that IL-1β and 
TNFα induce expression of MMP-3 and MMP-13. Consistently with these evidences, in 
our study we demonstrated that IL-1 stimulation in ATDC5 chondrogenic cells induced a 
remarkable increase of MMP13 levels and in the same time it reduced type II collagen 
compared with untreated cells. Butyrate reduces MMP13 expression and increases type II 
collagen, underlying its important role in limiting extracellular matrix disruption and 
consequentially in reducing the loss of collagen, important structural protein in healthy 
cartilage. Interestingly, all these butyrate activities were confirmed in mature chondrocytes 
derived by ATDC5 differentiation. 
We also showed that inflammatory response by IL-1 promote the significant 
increase of chemokines, class of small protein cytokines that act as chemoattractants to 
guide cells to migrate to a specific location, and in the context of inflammation, toward the 
site of injury or pathogenic invasion [251]. According to our findings, it has been clearly 
demonstrated that among these chemokines, serum fractalkine, or Cx3cl1, was 
significantly elevated in patients with knee OA in comparison to healthy individuals sera, 
while both serum and SF concentrations of the chemokine were associated with knee OA 
scores [261]. Furthermore, these chemokines, together with other pro-inflammatory 
mediators, are released in the synovial fluids of OA patients and contribute to the 
disruption of the balance between anabolism and catabolism [247, 411, 412]. 
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In our study we showed a marked increase in IL-1-induced Ccl3 (or MIP1-α), 
Cx3cl1 and AnxA1, known mediator of some glucocorticoid effects through the inhibition 
of PLA2 activity [413] and related to cyclooxygenase and inducible nitric oxide synthase 
expression [414]. Although its multiple functions [415], the main role ascribed to AnxA1 
is an anti-inflammatory activity. We hypothesized that AnxA1 increased expression is a 
compensatory mechanism, leading to limit inflammation. Interestingly, butyrate treatment 
increased the expression of Ccl3, Cx3cl1 and AnxA1 after stimulation with IL-1, 
suggesting its pro-resolving activity in inflammatory response. 
Some recent studies, which demonstrated the association and the strong positive 
connections between several members of HDACs inhibitors, such as butyrate, and the anti-
inflammatory pro-resolving molecule AnxA1 [416, 417]. However, the underlying 
mechanism of this chemoattractant effect of butyrate in chondrocyte was not still well 
investigated.  
The novelty of our data is the involvement of GPR43 in chemoattractant activity of 
butyrate in chondrocytes. Previously, the role of GPR43 in SCFA-induced neutrophil 
chemotaxis was determined in mice [76, 92], supporting the relevant role of this SCFA 
receptor on immune cells during inflammation [76, 93]. In particular, GPR43 seems to be 
the unique functional receptor for SCFAs on neutrophils [76]. In according with these data, 
we demonstrated the direct involvement of GPR43 on butyrate-induced chemotaxis in 
chondrocytes after IL-1 stimulation. In fact, GPR43 silencing in IL-1-stimulated 
chondrocytes made butyrate unable to induce the expression of Cx3cl1 and AnxA1, 
missing its chemoattractant effect. 
 
Conclusions 
 
In conclusion, we demonstrated the anti-inflammatory effects of sodium butyrate in 
ATDC5 chondrogenic cell line not only in reducing pro-inflammatory cytokines and 
adipokines, but also in decreasing the expression of important adhesion molecules and the 
activation of inflammatory or anti-apoptotic pathways. We also show that butyrate reduces 
MMPs production and the loss of collagen type 2, suggesting its capability to preserve 
cartilage integrity. Interestingly, butyrate anti-inflammatory effects were associated to the 
stimulation of neutrophil recruitment, increasing the expression of important chemokines 
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(Ccl3 and Cx3cl1) and the anti-inflammatory and resolving protein AnxA1. The efficacy 
of sodium butyrate in reducing inflammation in chondrocyte, closed-related with its 
chemoattractant effect, can suggest its clinical application as pro-resolving factor of 
cartilage inflammation for the treatment of OA and its related complications. 
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10.4 THERAPEUTIC EFFECT OF BUTYRATE AND ITS 
DERIVATIVE FBA IN ANIMAL MODELS OF WOUND HEALING 
INDUCED BY DOXORUBICIN OR MECHANICAL DAMAGE 
 
Preliminary conclusions 
 
In the gut, butyrate enhances cell proliferation, differentiation and maturation, and 
reduces apoptosis of normal enterocytes and colonocytes, through its influence on gene 
expression and protein synthesis [59]. A clear role for these cells has been identified in 
maintaining homeostasis and in repairing tissue damage. 
Wound healing is a highly dynamic process involving complex interactions of 
extracellular matrix molecules, soluble mediators, various resident cells, and infiltrating 
leukocyte subtypes. The healing process involves three phases that overlap in time and 
space: inflammation, tissue formation, and tissue remodeling. Synthesis, remodeling, and 
deposition of structural extracellular matrix molecules, are indispensable for initiating 
repair and progression into the healing state. Tissue injury causes the immediate onset of 
acute inflammation. It has long been considered that the inflammatory response is 
necessary in supplying growth factor and cytokine signals that orchestrate cell and tissue 
movements necessary for repair. Successful repair after tissue injury requires resolution of 
the inflammatory response [319]. 
However, whereas the knowledge about mechanisms and molecules inducing and 
ongoing the inflammatory response is increasing, molecules and underlined mechanisms 
that limit and down regulate this activity are less known. Such mechanisms might include: 
downregulation of chemokine expression by anti-inflammatory cytokines (i.e. IL-10, TGF-
?1), or up-regulation of anti-inflammatory molecules; or resolution of the inflammatory 
response mediated by the surface cells. Dysregulation of critical parameters of these 
interactions results in chronic inflammatory disease states that impair the quality of 
healing. However, the relevance of these mechanisms for cutaneous tissue repair has to be 
further investigated. 
In our study using two models of ulcers by doxorubicin or mechanical damage, we 
demonstrated that butyrate and its derivative FBA are able to improve wound healing in 
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rats and mice. These preliminary data demonstrate that both treatments, through oral or 
intradermic administration, accelerate and promote wound resolution process. 
In both experimental models, butyrate and FBA were able to accelerate and promote 
wound healing, inducing an early tissue repair. In particular, butyrate was able to act after 
local or systemic administration. Indeed, both intradermal and oral administration of the 
examined products reduced the time necessary to obtain wound resolution and tissue 
repair. The effect of butyrate and its derivative appears to be time- and concentration-
dependent. Further studies shell be required to determine butyrate mechanism of action to 
confirm its role as pro-resolving factor. 
The analysis of treated-skin lysates will allow the understanding of the mechanisms 
involved in butyrate-induced wound healing improvement. In particular, we will analyze 
whether butyrate would be able to modulate the expression of pivotal mediators involved 
in the first inflammatory phase, in tissue proliferation and matrix remodeling/regeneration. 
This study would strengthen butyrate capability in regulating the balance beetwen 
inflammation and repair. 
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GENERAL CONCLUSIONS 
 
Short-chain fatty acids are important end-products of probiotic fermentation, 
therefore they are considered “postbiotics”. Among the SCFAs produced in the human 
intestine, butyrate has been widely studied and has been shown to play an important role in 
the maintenance of colonic health. Increased butyrate production in the large intestine 
seems to be responsible for at least some of the protective effects of fermentable dietary 
fibre. The effects of butyrate are diverse and complex, and involve several distinct 
mechanisms that go beyond the classical connotation as an energy source for the intestinal 
epithelial cells. Frequently, butyrate mechanisms are ascribed to its effect on gene 
expression, as histone deacetylase inhibitor, and suppression of NF-kB activation. 
However, butyrate exerts many other activities, such as the inhibition of colonic 
carcinogenesis, inflammation and oxidative stress, the improvement of the colonic defence 
barrier function and the promotion of satiety by different mechanisms, acting not only at 
intestinal but also at extra-intestinal level. 
Here, about its intestinal effects, we examined the efficacy of butyrate and its 
derivative FBA in a murine model of DSS-induced colitis. Both compounds were able to 
restore gut integrity, avoiding bacterial translocation and modulating immune cell 
recruitment. Butyrate anti-inflammatory effects are associated not only to the reduction in 
neutrophil infiltration and HDAC9 transcription in colonic mucosa, but also to the 
recovery of the unbalance between pro-inflammatory and anti-inflammatory mediators, 
involved during colitis. In particular, we have demonstrated that the butyrate-releasing 
compound, FBA, restore PPAR-γ levels and block NF-kB activation, protecting 
colonocytes from inflammation. These events improve intestinal immune homeostasis and 
tolerance vs. commensal bacteria. 
Efficacy of butyrate to limit early molecular events underlying inflammatory process 
linked to intestinal damage, suggests its potential clinical utility as a preventive and 
therapeutic strategy for colitis. Indeed, FBA may represent an important therapeutic 
alternative to butyrate, favoring a better compliance and a greater effectiveness, since it 
lacks the characteristic odor of rancid cheese, its main negative characteristic associated to 
its instability.  
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However, the precise innate immune mechanisms of butyrate on beneficial host-microbial 
interactions are not yet fully understood. Peng et al. [418] demonstrated that butyrate 
enhances the intestinal barrier by facilitating tight junction assembly via activation of 
AMPK in Caco-2 cell monolayer. Furthermore, butyrate ability to improve gut integrity 
was also shown in a model of cow’s milk allergy (CMA) induced by BLG sensitization. In 
this model, mice were treated by daily gavage with 20 mg/kg of sodium butyrate, 
beginning two weeks prior to sensitization and continuing throughout the sensitization 
protocol. In this study we have displayed that oral administration of sodium butyrate 
ameliorated gut barrier integrity. 
BLG sensitization induces acute allergenic response, with the increase of ear 
swelling and hypersensitivity symptoms and the decrease in body temperature. Butyrate 
significantly decreases the innate immune response, reducing IgE and IL-4 levels, 
measured in plasma and spleen lysates, respectively. Efficacy of sodium butyrate to limit 
acute and immune allergenic response can suggest its possible clinical application for the 
treatment of cow’s milk protein allergy, especially in children. 
From June 2015 to February 2016, my study was focused on the anti-inflammatory 
effects of sodium butyrate in chondrocytes, and its chemoattractant activity, that was 
demonstrated for the first time mediated by GPR43. These experiments were performed in 
the laboratory of Dr. Oreste Gualillo (IDIS Institute), located in the Clinical Hospital in 
Santiago de Compostela, NEIRID Lab, thank to the COINOR fellowship (Programma 
STAR-Linea 2 “Mobilità Giovani Ricercatori”).  
We used IL-1 stimulated-ATDC5 cells, as in vitro model of OA. Butyrate not only 
reduces pro-inflammatory cytokines and adipokines involved in OA, but also decreases the 
expression of important adhesion molecules, inhibiting inflammatory and anti-apoptotic 
pathways. We also showed the butyrate capability to reduce MMPs production and the loss 
of collagen type 2, suggesting an improvement of cartilage disruption. Interestingly, 
butyrate anti-inflammatory effects were associated to its capability to stimulate neutrophil 
recruitment, increasing the expression of several chemokines (Ccl3 and Cx3cl1) and the 
anti-inflammatory protein AnxA1. This last effect was directly mediated by butyrate 
receptor GPR43.  
The pro-resolving effect of butyrate was also analyzed in two models of wound 
healing induced by doxorubicin or mechanical damage. Here, butyrate and FBA were able 
to reduce the repair time, when used systemically (by oral administration) or topically (by 
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intradermal injection). The protective effect of butyrate and its derivative on wound 
healing and tissue repair appeared to be time- and concentration-dependent. Further studies 
will be needed to determine the resolving pathway that are induced by butyrate. 
Since FBA does not have the characteristic odor of rancid cheese, this derivative may 
represent a viable therapeutic alternative to butyrate, favoring a better compliance and a 
greater effectiveness. 
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